0001140361-24-025068.txt : 20240509 0001140361-24-025068.hdr.sgml : 20240509 20240509084044 ACCESSION NUMBER: 0001140361-24-025068 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FEMASYS INC CENTRAL INDEX KEY: 0001339005 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 113713499 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40492 FILM NUMBER: 24928785 BUSINESS ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 770-500-3910 MAIL ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 10-Q 1 ef20026303_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to____________

Commission file number: 001-40492

	Femasys Inc.
	(Exact Name of Registrant as Specified in its Charter)

Delaware		11-3713499
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100
Suwanee, GA		30024
(Address of principal executive offices)		(Zip Code)

(770) 500-3910
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

	Title of each class		Trading symbol		Name of each exchange on which registered
	Common stock, $0.001 par value		FEMY		The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☑	Smaller reporting company ☑
Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The Registrant had 22,220,718 shares of common stock, $0.001 par value, outstanding as of May 8, 2024.

	TABLE OF CONTENTS
		Page

Part I. Financial Information
Item 1	Condensed Financial Statements	5
	Condensed Balance Sheets as of March 31, 2024 and December 31, 2023 (unaudited)	6
	Condensed Statements of Comprehensive Loss for the Three months ended March 31, 2024 and 2023 (unaudited)	7
	Condensed Statements of Stockholders’ Equity for the Three months ended March 31, 2024 and 2023 (unaudited)	8
	Condensed Statements of Cash Flows for the Three months ended March 31, 2024 and 2023 (unaudited)	9
	Condensed Notes to Financial Statements (unaudited)	10
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4	Controls and Procedures	22

Part II. Other Information
Item 1	Legal Proceedings	22
Item 1A	Risk Factors	23
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3	Defaults Upon Senior Securities	23
Item 4	Mine Safety Disclosures	23
Item 5	Other Information	23
Item 6	Exhibits	23
SIGNATURES		24

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:

•

our ability to develop and advance our current product candidates and programs into, and successfully initiate and complete, clinical trials;

•

the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results;

•

our ability to enroll subjects in the clinical trials for our product candidates in order to advance the development thereof on a timely basis;

•

our ability to successfully initiate and grow the commercial launch of FemaSeed®;

•

our ability to obtain additional financing to fund the clinical development and commercialization of our product candidate and products and fund our operations;

•

estimates regarding the total addressable market for our products and product candidate;

•

competitive companies and technologies in our industry;

•

our ability to obtain U.S. Food and Drug Administration (FDA) approval for our permanent birth control system, ability to establish and expand sales of our women-specific medical products and develop and commercialize additional products;

•

our ability to obtain regulatory approvals for and commercialize our product candidate, or the effect of delays in obtaining regulatory authorizations and commercialize;

•

our business model and strategic plans for our products, product candidate, technologies and business, including our implementation thereof;

•

commercial success and market acceptance of our products and product candidate;

•

our ability to achieve and maintain adequate levels of coverage or reimbursement for FemaSeed, FemBloc® or any future product candidates, and our products we may seek to commercialize;

•

our ability to manufacture our products and product candidates in compliance with applicable laws, regulations and requirements and to oversee third-party suppliers, service providers and vendors in the performance of any contracted activities in accordance with applicable laws, regulations and requirements;

•

our ability to accurately forecast customer demand for our product candidates, and manage our inventory;

•

our ability to build, manage and maintain our direct sales and marketing organization, and to market and sell our artificial insemination product, permanent birth control system, and women-specific medical product solutions in markets in and outside of the United States;

•

our ability to hire and retain our senior management and other highly qualified personnel;

•

FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets;

•

the timing or likelihood of regulatory filings and approvals or clearances;

•

our ability to establish and maintain intellectual property protection for our product candidates and our ability to avoid claims of infringement;

•

the volatility of the trading price of our common stock; and

•

our expectations about market trends.

Table of Contents

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report on Form 10-Q entitled “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this Quarterly Report on 10-Q are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM I.

Financial Statements

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

Assets	March 31, 2024			December 31, 2023
Current assets:
Cash and cash equivalents	$	17,835,968			21,716,077
Accounts receivable, net		120,529			98,906
Inventory, net		971,297			667,118
Prepaid and other current assets		955,539			695,879
Total current assets		19,883,333			23,177,980
Property and equipment, at cost:
Leasehold improvements		1,212,417			1,212,417
Office equipment		47,308			47,308
Furniture and fixtures		417,654			414,303
Machinery and equipment		2,582,220			2,559,356
Construction in progress		569,723			423,077
		4,829,322			4,656,461
Less accumulated depreciation		(3,615,405	)		(3,545,422	)
Net property and equipment		1,213,917			1,111,039
Long-term assets:
Lease right-of-use assets, net		2,227,561			2,380,225
Intangible assets, net of accumulated amortization		33,115			—
Other long-term assets		1,013,034			1,086,581
Total long-term assets		3,273,710			3,466,806

Total assets	$	24,370,960			27,755,825

(continued)

Table of Contents

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

Liabilities and Stockholders’ Equity	March 31, 2024			December 31, 2023
Current liabilities:
Accounts payable	$	1,095,730			1,137,823
Accrued expenses		673,457			1,444,296
Clinical holdback – current portion		93,376			65,300
Lease liabilities – current portion		494,967			406,636
Total current liabilities		2,357,530			3,054,055
Long-term liabilities:
Clinical holdback – long-term portion		30,389			54,935
Convertible notes payable, net (including related parties)		4,472,456			4,258,179
Lease liabilities – long-term portion		1,902,991			2,036,067
Total long-term liabilities		6,405,836			6,349,181
Total liabilities		8,763,366			9,403,236
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023		22,217			21,775
Treasury stock, 117,223 common shares		(60,000	)		(60,000	)
Warrants		2,631,838			2,787,137
Additional paid-in-capital		124,994,678			123,985,306
Accumulated deficit		(111,981,139	)		(108,381,629	)
Total stockholders’ equity		15,607,594			18,352,589

Total liabilities and stockholders’ equity	$	24,370,960			27,755,825

The accompanying notes are an integral part of these condensed unaudited financial statements.

Table of Contents

FEMASYS INC.

Condensed Statements of Comprehensive Loss

(unaudited)

	Three Months Ended March 31,
	2024			2023
Sales	$	271,140			293,984
Cost of sales (excluding depreciation expense)		88,532			105,120
Operating expenses:
Research and development		1,770,731			1,537,439
Sales and marketing		300,487			244,896
General and administrative		1,502,804			1,315,137
Depreciation and amortization		71,228			133,066
Total operating expenses		3,645,250			3,230,538
Loss from operations		(3,462,642	)		(3,041,674	)
Other income (expense):
Interest income		224,684			97,089
Interest expense		(361,552	)		(1,672	)
Total other income (expense)		(136,868	)		95,417

Net loss	$	(3,599,510	)		(2,946,257	)

Net loss attributable to common stockholders, basic and diluted	$	(3,599,510	)		(2,946,257	)

Net loss per share attributable to common stockholders, basic and diluted	$	(0.17	)		(0.25	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted		21,775,357			11,872,255

The accompanying notes are an integral part of these condensed unaudited financial statements.

Table of Contents

FEMASYS INC.

Condensed Statements of Stockholders’ Equity

(unaudited)


																		Total
	Common stock				Treasury common stock								Additional		Accumulated			stockholders’
	Shares		Amount		Shares		Amount			Warrants			paid-in capital		deficit			equity
THREE MONTHS ENDED MARCH 31, 2024
Balance at December 31, 2023		21,774,604	$	21,775		117,223	$	(60,000	)	$	2,787,137		$	123,985,306	$	(108,381,629	)	$	18,352,589

Share-based compensation expense		—		—		—		—			—			77,585		—			77,585
Issuance of common stock in connection with at-the-market offering, net of issuance costs		441,966		442		—		—			—			776,488		—			776,930
Expiration of warrant											(155,299	)		155,299
Net loss		—		—		—		—			—			—		(3,599,510	)		(3,599,510	)
Balance at March 31, 2024		22,216,570	$	22,217		117,223	$	(60,000	)	$	2,631,838		$	124,994,678	$	(111,981,139	)	$	15,607,594

THREE MONTHS ENDED MARCH 31, 2023
Balance at December 31, 2022		11,986,927	$	11,987		117,223	$	(60,000	)	$	567,972		$	108,857,065	$	(94,134,505	)	$	15,242,519

Issuance of common stock in connection with at-the-market offering, net of issuance costs		2,869		3		—		—			—			3,365		—			3,368
Share-based compensation expense		—		—		—		—			—			56,954		—			56,954
Net loss		—		—		—		—			—			—		(2,946,257	)		(2,946,257	)
Balance at March 31, 2023		11,989,796	$	11,990		117,223	$	(60,000	)	$	567,972		$	108,917,384	$	(97,080,762	)	$	12,356,584

The accompanying notes are an integral part of these condensed unaudited financial statements.

Table of Contents

FEMASYS INC.

Condensed Statements of Cash Flows

(unaudited)

	Three Months ended March 31,
	2024			2023
Cash flows from operating activities:
Net loss	$	(3,599,510	)		(2,946,257	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		69,983			131,653
Amortization		1,245			1,413
Amortization of right-of-use assets		152,664			75,635
Provision for bad debts		1,000			—
Inventory reserve write-off		1,240			300
Share-based compensation expense		77,585			56,954
Amortization of debt issuance costs and discount		258,802			—
Changes in operating assets and liabilities:
Accounts receivable		(22,623	)		(46,485	)
Inventory		(305,419	)		(64,318	)
Prepaid and other assets		(187,359	)		150,654
Accounts payable		(137,753	)		3,016
Accrued expenses		(792,239	)		78,703
Lease liabilities		(44,745	)		(91,211	)
Other liabilities		(40,995	)		2,306

Net cash used in operating activities		(4,568,124	)		(2,647,637	)
Cash flows from investing activities:
Acquisition of patents		(25,603	)		—
Purchases of property and equipment		(64,557	)		(8,901	)

Net cash used in investing activities		(90,160	)		(8,901	)
Cash flows from financing activities:
Proceeds from at-the-market sales of common stock		802,242			3,373
Issuance costs for at-the-market sales of common stock		(24,067	)		—
Repayment of note payable		—			(141,298	)
Payments under lease obligations		—			(6,135	)

Net cash provided by (used in) financing activities		778,175			(144,060	)

Net change in cash and cash equivalents		(3,880,109	)		(2,800,598	)
Cash and cash equivalents:
Beginning of period		21,716,077			12,961,936

End of period	$	17,835,968			10,161,338

Supplemental cash flow information
Cash paid for:
Interest	$	—			1,672
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued expense	$	108,304			12,990
Acquisition of patents included in accounts payable	$	8,757
Commissions costs relating to certain proceeds from issuance of common stock	$	—			109
Deferred offering costs reclassified to additional paid-in-capital	$	1,245			—

The accompanying notes are an integral part of these condensed unaudited financial statements.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

(1)	Organization, Nature of Business, and Liquidity

Organization and Nature of Business

Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. The Company’s mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.

Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv® is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method and is approved for sale in the U.S. and Canada. FemCath®, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc®, the Company’s solution for permanent birth control, is based on the Company’s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.

Basis of Presentation

The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report.

In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.

Liquidity

As of March 31, 2024, the Company had cash and cash equivalents of $17,835,968. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

For the three months ended March 31, 2024, the Company generated a net loss of $3,599,510. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed.

The Company believes that its cash and cash equivalents as of March 31, 2024 and cash received subsequent to quarter end (see Note 16, Subsequent Events) will be sufficient to fund our ongoing operations at least 12 months from the date of filing these condensed financial statements.

Recently Issued Accounting Pronouncements – Recently Adopted

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company’s financial statements and footnote disclosures.

Recently Issued Accounting Pronouncements – Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

(2)	Fair Value

The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets.

Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model‑based valuation techniques for which all significant assumptions are observable in the market.

Level 3 – Valuation is generated from model‑based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the asset or liability.

Certain of the Company’s financial instruments, including cash and cash equivalents, notes payable and other liabilities approximate their fair value because of the short‑term maturity of these financial instruments and are based on Level 1 inputs. The Company’s equity-classified warrants and stock options are measured at fair value upon grant using the Black-Scholes option pricing model, a Level 2 input. The Company uses unobservable inputs for the model’s assumptions, including management’s assumptions of the Company’s volatility and price of the underlying stock. The fair value of the Company’s convertible notes is disclosed at each reporting period based on a discounted cash flow analysis, a Level 3 input.

(3)	Cash and Cash Equivalents

As of March 31, 2024 and December 31, 2023, money market funds included in cash and cash equivalents on the balance sheets were $17,503,242 and $21,278,895, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets.

(4)	Inventories

Inventory stated at cost, net of reserve, consisted of the following:

	March 31,		December 31,
	2024		2023
Materials	$	574,199		367,934
Work in progress		131,657		128,993
Finished goods		265,441		170,191
Inventory, net	$	971,297		667,118

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

(5)	Accrued Expenses

Accrued expenses consisted of the following:

	March 31,		December 31,
	2024		2023
Clinical trial costs	$	243,367		276,141
Accrued interest		147,275		—
Incentive and other compensation costs		146,409		1,082,606
Director fees		70,000		60,210
Franchise taxes		12,800		12,160
Other		53,606		13,179
Accrued expenses	$	673,457		1,444,296

(6)	Clinical Holdback

The following table shows the activity within the clinical holdback liability accounts for the three months ended March 31, 2024:

Balance at December 31, 2023	$	120,235
Clinical holdback retained		3,530
Clinical holdback paid		—
Balance at March 31, 2024	$	123,765
Less: clinical holdback - current portion		(93,376	)
Clinical holdback - long-term portion	$	30,389

(7)	Revenue Recognition

Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three months ended March 31, 2024 and 2023, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of March 31, 2024 or 2023.

The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns.

The following table summarizes our sales, primarily from FemVue, by geographic region as follows:

	Three Months Ended March 31,
Primary geographical markets	2024		2023
U.S.	$	271,140		293,984
International		—		—
Total	$	271,140		293,984

(8)	Commitments and Contingencies

Legal Claims

Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with Accounting Standards Codification (ASC) 450, Contingencies, the Company will assess the likelihood of an adverse judgment for any outstanding claim as well as ranges of probable losses. When it has been determined that a loss is probable and the amount can be reasonably estimated, the Company will record a liability. For both periods presented, there were no material legal contingencies requiring accrual or disclosure.

The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of March 31, 2024 and December 31, 2023.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

(9)	Notes Payable

AFCO Credit Corporation (AFCO)

In June 2022, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate was 5.7% and the monthly installment payment was $47,539, which represents principal and interest. The final installment payment was paid in March of 2023.

In July 2023, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate was 8.6% and the monthly installment is $48,423, which represents principal and interest. The Promissory Note was paid in full without penalty in November 2023.

As of March 31, 2024, and December 31, 2023, there was no principal balance on the AFCO note in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $0 and $1,319 for the three months ended March 31, 2024 and 2023, respectively.

(10)	Convertible Notes with Warrants (November 2023 Financing)

On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs. The Company intends to use the net proceeds from the offering for general corporate purposes.

The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Company’s option, and mature on November 21, 2025, unless earlier converted or redeemed.

The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holder’s Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of March 31, 2024, the Convertible Notes have not been converted into shares of common stock.

The Warrants

The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied.

The Series B Warrants are exercisable immediately, together with the Series A Warrant Shares, and expire one year from the date of issuance. The Company has the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeds 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system.

The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:

	Series A Warrants			Series B Warrants
Expected term (in years)		5			1
Risk‑free interest rate		4.55	%		5.24	%
Dividend yield		—	%		—	%
Expected volatility		104.89	%		113.84	%
Exercise price	$	1.18		$	1.48
Stock price	$	0.95		$	0.95

Black-Scholes value	$	0.55		$	0.28

The November 2023 Financing proceeds of $6,850,000 net of $525,144 in transaction costs were allocated to the convertible notes and Series A and Series B Warrants using the relative fair value method. The valuation of the warrants was $2,219,165 and was recorded as a component of stockholders’ equity, and a total debt discount of $2,744,309. The convertible notes are recorded as a long-term liability, net of discount and issuance costs.

For the convertible notes for the quarter ended March 31, 2024, the Company recognized total interest expense of $361,552, including coupon interest expense of $102,750 amortization of debt discount and issuance costs of $258,802. As of December 31, 2023, the Notes principal balance as $6,850,000, unamortized discount was $2,636,346 and accrued interest was $44,525. As of March 31, 2024, the Notes principal balance as $6,850,000, unamortized discount was $2,377,544 and accrued interest was $147,275. The fair value of the convertible notes on March 31, 2024, calculated using a discounted cash flow analysis, was $6,185,934.

(11)	Stockholders’ Equity

On July 1, 2022, we filed a prospectus including an offering to sell up to $150 million in common and preferred stock, debt securities and warrants. Additionally, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler” or the “Sales Agent”) and filed a related prospectus establishing an “at-the-market” facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds up to $16.7 million at current market prices until all shares are sold. As of March 31, 2024, 3.9 million shares of common stock have been sold for aggregate proceeds of $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of March 31, 2024, the amount we are authorized to sell is subject to baby-shelf limitations.

In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering (“pre-funded warrants”) and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock (“common warrants”). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services (“placement agent warrants”), collectively the (“April 2023 Financing”). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764. The Company intends to use the net proceeds from the offering for general corporate purposes.

As of March 31, 2024, the Company had 22,099,347 shares of common stock outstanding, and no dividends have been declared or paid.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

(12)	Equity Incentive Plans and Warrants

Stock-Based Awards

(a)

Stock Option Plans

Activity under the Company’s stock option plans for the three months ended March 31, 2024 was as follows:

	Number of options			Weighted average exercise price
Outstanding at December 31, 2023		2,102,030		$	2.00
Granted		708,821			0.97
Forfeited		(62,618	)		2.59
Outstanding at March 31, 2024		2,748,233		$	1.72

Vested and exercisable at March 31, 2024		1,208,627		$	2.63

Options granted under our 2021 Stock Option Plan for the three months ended March 31, 2024 to employees and nonemployees were 706,321 and 2,500, respectively and the weighted average exercise prices were $0.97 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.83 and $0.39, respectively and were estimated using the following Black-Scholes assumptions:

	Employee			Nonemployee
Expected term (in years)		6.25			1.50
Risk‑free interest rate		3.87	%		4.53	%
Dividend yield		—	%		—	%
Expected volatility		109.65	%		105.34	%

No options were exercised for the three months ended March 31, 2024 under our stock option plans.

As of March 31, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 849,647.

(b)

Inducement Grants

On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions:

	Inducement
Expected term (in years)		6.25
Risk‑free interest rate		4.10	%
Dividend yield		—	%
Expected volatility		109.64	%

As of March 31, 2024, inducement grant awards of 250,000 shares were outstanding with a weighted average exercise price of $1.89, and 62,500 shares were vested and exercisable with a weighted average exercise price of $2.64.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

(c)

Share-Based Compensation Expense

The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss:

	Three Months Ended March 31,
	2024		2023
Research and development	$	30,327		25,059
Sales and marketing		6,199		(2,544	)
General and administrative		41,059		34,439
Total share-based compensation expense	$	77,585		56,954

As March 31, 2024, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,411,405, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,256,183 of unrecognized expense is expected to be recognized over a weighted average period of 3.3 years.

(d)

Employee Stock Purchase Plan (ESPP)

For the three months ended March 31, 2024, no shares of common stock were issued under the Company’s ESPP Plan. As of March 31, 2024, the total number of shares of common stock reserved for future awards under the ESPP Plan was 603,518.

(e)

April 2023 Financing

On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 11, Stockholders’ Equity), (ii) pre-funded warrants to purchase 1,878,722 shares of common stock, (iii) common warrants to purchase 3,196,722 shares of common stock. Additionally, common warrants to purchase 191,803 shares of common stock were issued to the placement agent compensation for services performed.

The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs.

The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.

The common stock was valued at $1,133,480, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions:

	Pre-funded warrants			Common warrants
Expected term (in years)		4			4
Risk‑free interest rate		3.83	%		3.83	%
Dividend yield		—	%		—	%
Expected volatility		100.25	%		100.25	%
Exercise price	$	0.0001		$	1.095
Stock price	$	0.86		$	0.86
Black-Scholes value	$	0.86		$	0.58

The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholders’ equity.

In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of March 31, 2024, 68,809 placement agent warrants remain outstanding.

(13)	Related‑Party Transactions

In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 9). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Company’s board of directors.

Table of Contents

FEMASYS INC.

Condensed Notes to Financial Statements

(unaudited)

During the year ended December 31, 2023 and quarters ended March 31, 2024 and 2023, a family member of the CEO was employed by the Company.

(14)	Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share:

	Three Months Ended March 31,
	2024			2023

Net loss attributable to common stockholders, basic & diluted	$	(3,599,510	)		(2,946,257	)

Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		21,775,357			11,872,255
Net loss per share attributable to common stockholders, basic and diluted	$	(0.17	)		(0.25	)

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

	March 31, 2024		March 31, 2023
Options to purchase common stock		2,998,233		1,036,495
Warrants to purchase common stock, in connection with April 2023 financing		68,809		—
Warrants to purchase common stock, in connection with November 2023 financing		11,610,166		—
Warrants to purchase common stock		201,578		233,460
Total potential shares		14,878,786		1,269,955

(15)	Income Taxes

The effective tax rate of 0% for the three months ended March 31, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position.

(16)	Subsequent Events

In April 2024, the Company sold 121,371 shares under the at-the-market facility, resulting in gross cash proceeds of $219,752.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or the SEC, on March 28, 2024. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “goal,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar expressions intended to identify forward-looking statements and reflect our beliefs and opinions on the relevant subject. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. These statements are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Overview

We are a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. Our mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed and FemVue) or permanent birth control (FemBloc). We are a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 180 patents globally, in- house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop and commercialize products. Our suite of products and product candidates address what we believe are multi-billion dollar global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm.

Corporate Update

On October 26, 2023, we announced the completion of the European Union Medical Device Regulation (MDR) final audit which is the last step in obtaining an MDR certificate and CE marking.

On November 15, 2023, we secured a $6.85 million financing with a strategic investment from investors led by PharmaCyte Biotech.

On November 28, 2023, we announced the completion of enrollment of FemaSeed pivotal trial in support of commercial launch.

On January 23, 2024 and January 26, 2024, we announced initiation of enrollment in pivotal trial (NCT05977751) of our permanent birth control candidate FemBloc at two academic sites, for a total of six active sites, the maximum number permitted in the first stage.

On February 6, 2024, we announced the appointment of Richard Spector to new position of Chief Commercial Officer.

On March 6, 2024, we announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site.

On March 20, 2024, we announced positive topline data from pivotal trial for FDA-cleared FemaSeed for the treatment of infertility.

Clinical Update

FemaSeed – Our Intratubal Artificial Insemination Solution. In September 2023 we announced 510(k) clearance from the FDA for FemaSeed for intratubal insemination. The clinical trial was still ongoing at the time of receiving U.S. regulatory clearance from the FDA, however, the study was concluded with enrollment completed in November 2023. Topline results of the clinical trial were announced in March 2024. The trial demonstrated that 24% of women became pregnant after FemaSeed with male factor infertility (1 million to 20 million total motile sperm count (TMSC)). In contrast, the historical control indicated a 6.7% pregnancy rate by cycle for intrauterine insemination (IUI) with male factor infertility (greater than 1 million TMSC). Although subjects were permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The majority of adverse events were reported as mild (n=127 subjects, 216 cycles). No new safety concerns were observed through the seven-week follow-up. All adverse events were consistent with those known for IUI. The approved labeling includes women or couples wishing to become pregnant by way of intratubal insemination. The recruitment of the commercial team began with the hire of the Chief Commercial Officer in February 2024. In March 2024, the first commercial use of FemaSeed at a former investigative site was announced. Recruitment of the commercial team is underway.

FemBloc – Our Permanent Birth Control Solution. In June 2023 we received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 we announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have used FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market. All six sites permitted in the initial stage of the trial were announced as actively enrolling subjects in January 2024.

Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2024 and 2023

The following table shows our results of operations for the three months ended March 31, 2024 and 2023:

	Three Months Ended March 31,
	2024			2023			Change			% Change
Sales	$	271,140			293,984			(22,844	)		-7.8	%
Cost of sales (excluding depreciation expense)		88,532			105,120			(16,588	)		-15.8	%

Operating expenses:
Research and development		1,770,731			1,537,439			233,292			15.2	%
Sales and marketing		300,487			244,896			55,591			22.7	%
General and administrative		1,502,804			1,315,137			187,667			14.3	%
Depreciation and amortization		71,228			133,066			(61,838	)		-46.5	%
Total operating expenses		3,645,250			3,230,538			414,712			12.8	%
Loss from operations		(3,462,642	)		(3,041,674	)		(420,968	)		13.8	%
Other income (expense):
Interest income		224,684			97,089			127,595			131.4	%
Interest expense		(361,552	)		(1,672	)		(359,880	)		21523.9	%
Other income (expense)		(136,868	)		95,417			(232,285	)		-243.4	%
Net loss	$	(3,599,510	)		(2,946,257	)		(653,253	)		22.2	%

Sales

Sales decreased by $22,844, or 7.8%, to $271,140 for the three months ended March 31, 2024 from $293,984 for the three months ended March 31, 2023, attributable entirely to U.S. sales. Units sold decreased by 5.1% for the comparable periods, while maintaining a consistent average selling price.

Cost of sales

Cost of sales decreased by $16,588 or 15.8%, to $88,532 for the three months ended March 31, 2024 from $105,120 for the three months ended March 31, 2023. The decrease is primarily attributed to reduced sales and certain manufacturing efficiencies.

Research and development

The following table summarizes our R&D expenses incurred during the periods presented:

	Three Months Ended March 31,
	2024		2023
Compensation and related personnel costs	$	989,057		900,288
Clinical-related costs		438,775		366,360
Material and development costs		143,699		167,161
Professional and outside consultant costs		168,182		91,935
Other costs		31,018		11,695
Total research and development expenses	$	1,770,731		1,537,439

R&D expenses increased by $233,292 or 15.2%, to $1,770,731 for the three months ended March 31, 2024 from $1,537,439 for the three months ended March 31, 2023. The increase relates primarily to increased compensation costs, clinical-related costs, and professional and outside consultant costs, partially offset by reduced material and development costs.

Table of Contents

Sales and marketing

Sales and marketing expenses increased by $55,591 or 22.7%, to $300,487 for the three months ended March 31, 2024 from $244,896 for the three months ended March 31, 2023. The increase is largely due to increased compensation costs as we began hiring commercial team members.

General and administrative

General and administrative expenses increased by $187,667, or 14.3%, to $1,502,804 for the three months ended March 31, 2024 from $1,315,137 for the three months ended March 31, 2023. The increase was largely due to increased facility, overhead and compensation costs.

Depreciation and amortization

Depreciation and amortization expenses decreased by $61,838, or 46.5%, to $71,228 for the three months ended March 31, 2024 from $133,066 for the three months ended March 31, 2023. The decrease is due to a reduction of amortization expense associated with our intangible assets and depreciation expense associated with our fixed assets.

Other income (expense), net

Other income (expense), net decreased by $232,285, or 243.4%, to $136,868 of expense for the three months ended March 31, 2024 from $95,417 of income for the three months ended March 31, 2023. The decrease relates to interest expense and non-cash discount amortization related to the convertible notes payable, partially offset by an increase in interest income.

Liquidity and Capital Resources

Sources of liquidity

Since our inception through March 31, 2024, our operations have been financed primarily by net proceeds from the sale of our common stock and convertible preferred stock, indebtedness and, to a lesser extent, product revenue. As of March 31, 2024, we had $17,835,968 of cash and cash equivalents and an accumulated deficit of $111,981,139.

On July 1, 2022, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (the “Sales Agent”) and filed a related prospectus establishing an “at-the-market” facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares of common stock for an aggregate price up to $16.7 million pursuant to the prospectus. As of March 31, 2024, approximately 3.8 million shares of common stock have been sold for aggregate proceeds of $8.5 million under the Equity Distribution Agreement pursuant to the prospectus. As of March 31, 2024, the amount we are authorized to sell is subject to baby-shelf limitations.

In April 2023, we sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock. Additionally, common warrants were issued to the placement agent in this transaction to purchase up to 191,803 shares of common stock as compensation for services, collectively the (“April 2023 Financing”). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The net proceeds from the April 2023 Financing at closing were approximately $3.4 million. The pre-funded and common warrants in the April 2023 Financing were fully exercised for cash for additional proceeds of $3.5 million. Placement agent warrants of 68,809 remain outstanding as of March 31, 2024.

In November 2023, we entered into a securities purchase agreement with certain accredited investors pursuant to which we sold (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share (collectively, the “November Private Placement”). Net proceeds from the November Private Placement were $6.3 million. If exercised for cash, the warrants issued in the November Private Placement could result in proceeds of up to an additional $15.4 million.

Funding requirements

Based on our current operating plan, our current cash and cash equivalents are expected to be sufficient to fund our ongoing operations into the second half of 2025. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate.

Our cash and cash equivalents as of March 31, 2024 will not be sufficient to fund all of our product candidates through regulatory approval, and we anticipate needing to raise additional capital to complete the development and commercialization of our product candidates. However, we can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds will be available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify, or delay the development of our product candidates, or we may need to obtain funds through collaborations or otherwise on terms that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise adequate additional capital as and when required in the future, we could be forced to cease development activities and terminate our operations, and you could experience a complete loss of your investment.

Table of Contents

Cash Flows

Comparison of the Three months ended March 31, 2024 and 2023

The following table summarizes our cash flows for the three months ended March 31, 2024 and 2023:

	Three Months Ended March 31,
	2024			2023
Net cash used in operating activities	$	(4,568,124	)		(2,647,637	)
Net cash used in investing activities		(90,160	)		(8,901	)
Net cash provided by (used in) financing activities		778,175			(144,060	)
Net change in cash and cash equivalents	$	(3,880,109	)		(2,800,598	)

Operating activities

For the three months ended March 31, 2024, cash used in operating activities was $4,568,124, attributable to a net loss of $3,599,510 and a net change in our net operating assets and liabilities of $1,531,133, partially offset by non-cash charges of $562,519. Non-cash charges primarily consisted of $258,802 in amortization of the discount on convertible notes, $152,664 in right-of-use amortization, $77,585 in share-based compensation and $71,228 in depreciation and amortization. The change in our net operating assets and liabilities was primarily due to a decrease in accounts payable and accrued expenses of $929,992, increases in accounts receivable and prepaid and other assets of $209,982 and inventory of $305,419.

For the three months ended March 31, 2023, cash used in operating activities was $2,647,637, attributable to a net loss of $2,946,257, offset by a net change in our net operating assets and liabilities of $32,666 and non-cash charges of $265,955. Non-cash charges largely consisted of $133,066 in depreciation and amortization, $75,635 in right-of-use amortization, and $56,954 in share-based compensation. The change in our net operating assets and liabilities was primarily due to a decrease of $104,169 in accounts receivable and prepaid and other assets, an increase in accounts payable and accrued expenses of $81,719, partially offset by an increase of $64,318 in inventory and decrease of $91,211 in lease liabilities.

Investing activities

For the three months ended March 31, 2024, cash used in investing activities for the purchase of property and equipment and acquisition of patents was $90,160.

For the three months ended March 31, 2023, cash used in investing activities for the purchase of property and equipment was $8,901.

Financing activities

For the three months ended March 31, 2024, cash provided by financing activities was $778,175, attributable to proceeds from sales under the at-the-market facility, net of issuance costs.

For the three months ended March 31, 2023, cash used in financing activities was $144,060, attributable to repayments on notes payable of $141,298, payments under lease obligations of $6,135, offset by proceeds from issuance of common stock of $3,373.

Critical Accounting Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

While our significant accounting policies are more fully described in Note 2 to our financial statements appearing the Annual Report on Form 10-K for the year ended December 31, 2023 as filed on March 28, 2024, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.

Revenue recognition

Our policy is to recognize revenue when a customer obtains control of the promised goods under Accounting Standards Update (ASU) 2020-05, Revenue from Contracts with Customers (Topic 606), which we adopted effective January 1, 2018. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods, and we have elected to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price. We do not have multiple performance obligations in our customer orders, so revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time.

Table of Contents

The majority of products sold directly to U.S. customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. As of March 31, 2024, we have not had a history of significant returns.

Accrued expenses

We accrue expenses for estimated costs of R&D activities conducted by our third-party service providers, which include the conduct of preclinical studies and clinical trials. We record the estimated costs of R&D activities based upon the estimated amount of services provided but not yet invoiced. These costs, at times, may be a significant component of the research and development expenses and the Company makes estimates in determining the accrued expense each period. As actual costs become known, the Company adjusts its accrual. These accrued R&D costs are included in accrued expenses on the balance sheet and within R&D expense on the statement of comprehensive loss.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act are (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to our management, including to our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our management has concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2024.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial and accounting officer), does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.

PART II OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time we may be involved in legal proceedings arising in connection with our business. Based on information currently available, we believe that the amount, or range, of reasonably possible losses in connection with any pending actions against us in excess of established reserves, in the aggregate, is not material to our financial condition or cash flows. However, losses may be material to our operating results for any particular future period, depending on the level of income for such period.

Table of Contents

Item 1A.

Risk Factors

As of the date of this report, there are no material changes to our risk factors as previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

During the period covered by this Quarterly Report, none of the Company’s directors or executive officers have adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

Item 6.

Exhibits

			Incorporated by Reference
Exhibit			File
Number	Description of Document	Schedule/Form	Number	Exhibit	Filing Date

3.1	Eleventh Amended and Restated Certificate of Incorporation of Femasys Inc.	Form 8-K	001-40492	3.1	June 22, 2021

3.2	Amended and Restated Bylaws of Femasys Inc.	Form 8-K	001-40492	3.2	June 22, 2021

3.3	First Amendment to the Amended and Restated Bylaws of Femasys Inc.	Form 8-K	001-40492	3.1	March 30, 2023

31.1*	Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*	Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH*	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*	Inline XBRL Taxonomy Definition Linkbase Document

101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia, on this 9^th day of May 2024.

FEMASYS INC.

Dated: May 9, 2024	By: /s/ Kathy Lee-Sepsick
	Kathy Lee-Sepsick
	Chief Executive Officer and President

Dated: May 9, 2024
	By: /s/ Dov Elefant
	Dov Elefant
	Chief Financial Officer

EX-31.1 2 ef20026303_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kathy Lee-Sepsick, certify that:

1. I have reviewed this Report on Form 10-Q for Femasys Inc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	FEMASYS INC.

Date: May 9, 2024	By:	/s/ Kathy Lee-Sepsick
		Kathy Lee-Sepsick
		Chief Executive Officer and President
		(principal executive officer)

EX-31.2 3 ef20026303_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dov Elefant, certify that:

1. I have reviewed this Report on Form 10-Q for Femasys Inc;

b. Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	FEMASYS INC.

Date: May 9, 2024	By:	/s/ Dov Elefant
		Dov Elefant
		Chief Financial Officer
		(principal financial and accounting officer)

EX-32.1 4 ef20026303_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Femasys Inc., a Delaware Corporation, (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	FEMASYS INC.

Date: May 9, 2024	By:	/s/ Kathy Lee-Sepsick
		Kathy Lee-Sepsick
		Chief Executive Officer and President
		(principal executive officer)

EX-32.2 5 ef20026303_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	FEMASYS INC.

Date: May 9, 2024	By:	/s/ Dov Elefant
		Dov Elefant
		Chief Financial Officer
		(principal financial and accounting officer)

EX-101.SCH 6 femy-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization, Nature of Business, and Liquidity link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Clinical Holdback link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Equity Incentive Plans and Warrants link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 061600 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 061700 - Disclosure - Insider Trading Arrangements link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - Organization, Nature of Business, and Liquidity (Policies) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Clinical Holdback (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - Equity Incentive Plans and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 081400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Organization, Nature of Business, and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Clinical Holdback (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details) link:presentationLink link:calculationLink link:definitionLink 091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details) link:presentationLink link:calculationLink link:definitionLink 091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 091208 - Disclosure - Equity Incentive Plans and Warrants, April 2023 Financing (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 091600 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 femy-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 femy-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 femy-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts receivable, net Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in-capital Amortization of debt issuance costs and discount Amortization of debt discount and issuance costs Depreciation Depreciation Amortization Amortization of Intangible Assets Balance Sheets [Abstract] Net loss per share attributable to common stockholders, basic (in dollars per share) Net loss per share attributable to common stockholders, basic (in dollars per share) Cash and cash equivalents Interest Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Changes in operating assets and liabilities: Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, authorized (in shares) Common stock, issued (in shares) Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Common stock, $.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023 Construction in progress Convertible Notes [Member] Convertible notes payable, net (including related parties) Cost of sales (excluding depreciation expense) Total current liabilities Liabilities, Current Current liabilities: Maturity date Notes Payable Debt Disclosure [Text Block] Aggregate principal amount Notes principal balance Frequency of installment payments Convertible note accrue interest rate Interest rate Maturity date of loan Debt Instrument, Maturity Date Debt Instrument, Name [Domain] Monthly principal and interest payments Debt discount Convertible Notes [Abstract] Notes Payable [Abstract] Debt Instrument [Axis] Debt Instrument [Line Items] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Transaction costs Payments of Debt Issuance Costs Depreciation and amortization Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Net loss per share attributable to common stockholders, diluted (in dollars per share) Net loss per share attributable to common stockholders, diluted (in dollars per share) Effective tax rate Effective Income Tax Rate Reconciliation, Percent [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Expense Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Furniture and fixtures General and administrative General and Administrative [Member] Statements of Comprehensive Loss [Abstract] Income Taxes [Text Block] Prepaid and other assets Increase (Decrease) in Other Operating Assets Warrants to purchase common stock (in shares) Options to purchase common stock (in shares) Intangible assets, net of accumulated amortization Interest expense Interest Expense Interest expense on loan Interest expense Interest Expense, Debt Finished goods Inventory, net Inventory, net Materials Work in progress Leasehold improvements Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Line of Credit Facility, Lender [Domain] Lender Name [Axis] Money Market Funds [Member] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net loss Net loss Net loss attributable to common stockholders, basic Net loss attributable to common stockholders, basic Total other income (expense) Nonoperating Income (Expense) Other income (expense): Long-term assets: Total long-term liabilities Liabilities, Noncurrent Long-term liabilities: Note payable Loss from operations Operating Income (Loss) Organization, Nature of Business, and Liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepaid and other current assets Proceeds from convertible notes Proceeds from Convertible Debt Proceeds from at-the-market sales of common stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Gross proceeds from offering Proceeds from Issuance or Sale of Equity Issuance Sale of Common Stock [Abstract] Proceeds to pay insurance premiums Proceeds from Notes Payable Property and equipment, gross Property, Plant and Equipment, Gross Net property and equipment Property, Plant and Equipment, Net Provision for bad debts Acquisition of patents Payments to Acquire Intangible Assets Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Related-party transaction Related-Party Transactions Repayment of note payable Down payments Repayments of Notes Payable Issuance costs for at-the-market sales of common stock Payments for Repurchase of Common Stock Accumulated deficit Sale of Stock [Domain] Sale of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Purchase price (in dollars per share) Gross cash proceeds from offering Net proceeds from issuance of common stock and warrants Inventories Share-based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Sales and marketing Sales and Marketing [Member] Share-based compensation expense expected to be recognized for employees and nonemployees Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Weighted-average fair values of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Weighted average exercise price (in dollars per share) Ending balance (in dollars per share) Beginning balance (in dollars per share) Dividend yield Expected volatility Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Statements of Cash Flows [Abstract] Statements of Stockholders' Equity [Abstract] Stockholders' equity: Stockholders Equity [Abstract] Warrants outstanding (in shares) Stockholders' Equity Equity [Text Block] Warrants purchase shares of common stock (in shares) Warrants issued to purchase common stock (in shares) Warrants issued to purchase common stock (in shares) Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Supplemental cash flow information Total current assets Assets, Current Current assets: Warrants Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Total potential shares (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) Common Stock [Member] Property and equipment, at cost: Research and development Total assets Assets EX-101.PRE 10 femy-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	May 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	001-40492
Entity Registrant Name	Femasys Inc.
Entity Central Index Key	0001339005
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3713499
Entity Address, Address Line One	3950 Johns Creek Court
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	500-3910
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	FEMY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,220,718

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 17,835,968	$ 21,716,077
Accounts receivable, net	120,529	98,906
Inventory, net	971,297	667,118
Prepaid and other current assets	955,539	695,879
Total current assets	19,883,333	23,177,980
Property and equipment, at cost:
Leasehold improvements	1,212,417	1,212,417
Office equipment	47,308	47,308
Furniture and fixtures	417,654	414,303
Machinery and equipment	2,582,220	2,559,356
Construction in progress	569,723	423,077
Property and equipment, gross	4,829,322	4,656,461
Less accumulated depreciation	(3,615,405)	(3,545,422)
Net property and equipment	1,213,917	1,111,039
Long-term assets:
Lease right-of-use assets, net	2,227,561	2,380,225
Intangible assets, net of accumulated amortization	33,115	0
Other long-term assets	1,013,034	1,086,581
Total long-term assets	3,273,710	3,466,806
Total assets	24,370,960	27,755,825
Current liabilities:
Accounts payable	1,095,730	1,137,823
Accrued expenses	673,457	1,444,296
Clinical holdback - current portion	93,376	65,300
Lease liabilities - current portion	494,967	406,636
Total current liabilities	2,357,530	3,054,055
Long-term liabilities:
Clinical holdback - long-term portion	30,389	54,935
Convertible notes payable, net (including related parties)	4,472,456	4,258,179
Lease liabilities - long-term portion	1,902,991	2,036,067
Total long-term liabilities	6,405,836	6,349,181
Total liabilities	8,763,366	9,403,236
Commitments and contingencies
Stockholders' equity:
Common stock, $.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023	22,217	21,775
Treasury stock, 117,223 common shares	(60,000)	(60,000)
Warrants	2,631,838	2,787,137
Additional paid-in-capital	124,994,678	123,985,306
Accumulated deficit	(111,981,139)	(108,381,629)
Total stockholders' equity	15,607,594	18,352,589
Total liabilities and stockholders' equity	$ 24,370,960	$ 27,755,825

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	22,216,570	21,774,604
Common stock, outstanding (in shares)	22,099,347	21,657,381
Treasury stock, common shares (in shares)	117,223	117,223

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended
Condensed Statements of Comprehensive Loss - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Statements of Comprehensive Loss [Abstract]
Sales	$ 271,140	$ 293,984
Cost of sales (excluding depreciation expense)	88,532	105,120
Operating expenses:
Research and development	1,770,731	1,537,439
Sales and marketing	300,487	244,896
General and administrative	1,502,804	1,315,137
Depreciation and amortization	71,228	133,066
Total operating expenses	3,645,250	3,230,538
Loss from operations	(3,462,642)	(3,041,674)
Other income (expense):
Interest income	224,684	97,089
Interest expense	(361,552)	(1,672)
Total other income (expense)	(136,868)	95,417
Net loss	(3,599,510)	(2,946,257)
Net loss attributable to common stockholders, basic	(3,599,510)	(2,946,257)
Net loss attributable to common stockholders, diluted	$ (3,599,510)	$ (2,946,257)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.17)	$ (0.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.17)	$ (0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	21,775,357	11,872,255
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	21,775,357	11,872,255

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Treasury Common Stock [Member]	Warrants [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2022	$ 11,987	$ (60,000)	$ 567,972	$ 108,857,065	$ (94,134,505)	$ 15,242,519
Balance (in shares) at Dec. 31, 2022	11,986,927
Treasury stock, common shares (in shares) at Dec. 31, 2022		117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with at-the-market offering, net of issuance costs	$ 3	$ 0	0	3,365	0	3,368
Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)	2,869	0
Share-based compensation expense	$ 0	$ 0	0	56,954	0	56,954
Net loss	0	$ 0	0	0	(2,946,257)	(2,946,257)
Treasury stock, common shares (in shares) at Mar. 31, 2023		117,223
Balance at Mar. 31, 2023	$ 11,990	$ (60,000)	567,972	108,917,384	(97,080,762)	12,356,584
Balance (in shares) at Mar. 31, 2023	11,989,796
Balance at Dec. 31, 2023	$ 21,775	$ (60,000)	2,787,137	123,985,306	(108,381,629)	$ 18,352,589
Balance (in shares) at Dec. 31, 2023	21,774,604					21,774,604
Treasury stock, common shares (in shares) at Dec. 31, 2023		117,223				117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with at-the-market offering, net of issuance costs	$ 442	$ 0	0	776,488	0	$ 776,930
Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)	441,966	0
Expiration of Warrant			(155,299)	155,299
Share-based compensation expense	$ 0	$ 0	0	77,585	0	77,585
Net loss	0	$ 0	0	0	(3,599,510)	$ (3,599,510)
Treasury stock, common shares (in shares) at Mar. 31, 2024		117,223				117,223
Balance at Mar. 31, 2024	$ 22,217	$ (60,000)	$ 2,631,838	$ 124,994,678	$ (111,981,139)	$ 15,607,594
Balance (in shares) at Mar. 31, 2024	22,216,570					22,216,570

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
Condensed Statements of Cash Flows - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (3,599,510)	$ (2,946,257)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	69,983	131,653
Amortization	1,245	1,413
Amortization of right-of-use assets	152,664	75,635
Provision for bad debts	1,000	0
Inventory reserve write-off	1,240	300
Share-based compensation expense	77,585	56,954
Amortization of debt issuance costs and discount	258,802	0
Changes in operating assets and liabilities:
Accounts receivable	(22,623)	(46,485)
Inventory	(305,419)	(64,318)
Prepaid and other assets	(187,359)	150,654
Accounts payable	(137,753)	3,016
Accrued expenses	(792,239)	78,703
Lease liabilities	(44,745)	(91,211)
Other liabilities	(40,995)	2,306
Net cash used in operating activities	(4,568,124)	(2,647,637)
Cash flows from investing activities:
Acquisition of patents	(25,603)	0
Purchases of property and equipment	(64,557)	(8,901)
Net cash used in investing activities	(90,160)	(8,901)
Cash flows from financing activities:
Proceeds from at-the-market sales of common stock	802,242	3,373	$ 8,700,000
Issuance costs for at-the-market sales of common stock	(24,067)	0
Repayment of note payable	0	(141,298)
Payments under lease obligations	0	(6,135)
Net cash provided by (used in) financing activities	778,175	(144,060)
Net change in cash and cash equivalents	(3,880,109)	(2,800,598)
Cash and cash equivalents:
Beginning of period	21,716,077	12,961,936
End of period	17,835,968	10,161,338	$ 17,835,968
Cash paid for:
Interest	0	1,672
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued expense	108,304	12,990
Acquisition of patents included in accounts payable	8,757
Commissions costs relating to certain proceeds from issuance of common stock	0	109
Deferred offering costs reclassified to additional paid-in-capital	$ 1,245	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization, Nature of Business, and Liquidity

3 Months Ended

Mar. 31, 2024

Organization, Nature of Business, and Liquidity [Abstract]

Organization, Nature of Business, and Liquidity

(1)	Organization, Nature of Business, and Liquidity

Organization and Nature of Business

Basis of Presentation

Use of Estimates

Liquidity

Recently Issued Accounting Pronouncements – Recently Adopted

Recently Issued Accounting Pronouncements – Not Yet Adopted

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Fair Value

3 Months Ended

Mar. 31, 2024

Fair Value [Abstract]

Fair Value [Text Block]

(2)	Fair Value

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

3 Months Ended

Mar. 31, 2024

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents

(3)	Cash and Cash Equivalents

XML 21 R10.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2024

Inventories [Abstract]

Inventories

(4)	Inventories

Inventory stated at cost, net of reserve, consisted of the following:

	March 31,		December 31,
	2024		2023
Materials	$	574,199		367,934
Work in progress		131,657		128,993
Finished goods		265,441		170,191
Inventory, net	$	971,297		667,118

XML 22 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2024

Accrued Expenses [Abstract]

Accrued Expenses

(5)	Accrued Expenses

Accrued expenses consisted of the following:

	March 31,		December 31,
	2024		2023
Clinical trial costs	$	243,367		276,141
Accrued interest		147,275		—
Incentive and other compensation costs		146,409		1,082,606
Director fees		70,000		60,210
Franchise taxes		12,800		12,160
Other		53,606		13,179
Accrued expenses	$	673,457		1,444,296

XML 23 R12.htm IDEA: XBRL DOCUMENT

Clinical Holdback

3 Months Ended

Mar. 31, 2024

Clinical Holdback [Abstract]

Clinical Holdback

(6)	Clinical Holdback

The following table shows the activity within the clinical holdback liability accounts for the three months ended March 31, 2024:

Balance at December 31, 2023	$	120,235
Clinical holdback retained		3,530
Clinical holdback paid		—
Balance at March 31, 2024	$	123,765
Less: clinical holdback - current portion		(93,376	)
Clinical holdback - long-term portion	$	30,389

XML 24 R13.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2024

Revenue Recognition [Abstract]

Revenue Recognition

(7)	Revenue Recognition

The following table summarizes our sales, primarily from FemVue, by geographic region as follows:

	Three Months Ended March 31,
Primary geographical markets	2024		2023
U.S.	$	271,140		293,984
International		—		—
Total	$	271,140		293,984

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies [Abstract]

Commitments and Contingencies

(8)	Commitments and Contingencies

Legal Claims

XML 26 R15.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Mar. 31, 2024

Notes Payable [Abstract]

Notes Payable

(9)	Notes Payable

AFCO Credit Corporation (AFCO)

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Convertible Notes with Warrants (November 2023 Financing)

3 Months Ended

Mar. 31, 2024

Convertible Notes with Warrants (November 2023 Financing) [Abstract]

Convertible Notes with Warrants (November 2023 Financing)

(10)	Convertible Notes with Warrants (November 2023 Financing)

The Warrants

The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:

	Series A Warrants			Series B Warrants
Expected term (in years)		5			1
Risk‑free interest rate		4.55	%		5.24	%
Dividend yield		—	%		—	%
Expected volatility		104.89	%		113.84	%
Exercise price	$	1.18		$	1.48
Stock price	$	0.95		$	0.95

Black-Scholes value	$	0.55		$	0.28

XML 28 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2024

Stockholders' Equity [Abstract]

Stockholders' Equity

(11)	Stockholders’ Equity

As of March 31, 2024, the Company had 22,099,347 shares of common stock outstanding, and no dividends have been declared or paid.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants

3 Months Ended

Mar. 31, 2024

Equity Incentive Plans and Warrants [Abstract]

Equity Incentive Plans and Warrants

(12)	Equity Incentive Plans and Warrants

Stock-Based Awards

(a)

Stock Option Plans

Activity under the Company’s stock option plans for the three months ended March 31, 2024 was as follows:

	Number of options			Weighted average exercise price
Outstanding at December 31, 2023		2,102,030		$	2.00
Granted		708,821			0.97
Forfeited		(62,618	)		2.59
Outstanding at March 31, 2024		2,748,233		$	1.72

Vested and exercisable at March 31, 2024		1,208,627		$	2.63

	Employee			Nonemployee
Expected term (in years)		6.25			1.50
Risk‑free interest rate		3.87	%		4.53	%
Dividend yield		—	%		—	%
Expected volatility		109.65	%		105.34	%

No options were exercised for the three months ended March 31, 2024 under our stock option plans.

As of March 31, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 849,647.

(b)

Inducement Grants

	Inducement
Expected term (in years)		6.25
Risk‑free interest rate		4.10	%
Dividend yield		—	%
Expected volatility		109.64	%

(c)

Share-Based Compensation Expense

	Three Months Ended March 31,
	2024		2023
Research and development	$	30,327		25,059
Sales and marketing		6,199		(2,544	)
General and administrative		41,059		34,439
Total share-based compensation expense	$	77,585		56,954

(d)

Employee Stock Purchase Plan (ESPP)

(e)

April 2023 Financing

	Pre-funded warrants			Common warrants
Expected term (in years)		4			4
Risk‑free interest rate		3.83	%		3.83	%
Dividend yield		—	%		—	%
Expected volatility		100.25	%		100.25	%
Exercise price	$	0.0001		$	1.095
Stock price	$	0.86		$	0.86
Black-Scholes value	$	0.86		$	0.58

XML 30 R19.htm IDEA: XBRL DOCUMENT

Related-Party Transactions

3 Months Ended

Mar. 31, 2024

Related-Party Transactions

(13)	Related‑Party Transactions

During the year ended December 31, 2023 and quarters ended March 31, 2024 and 2023, a family member of the CEO was employed by the Company.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2024

Net Loss per Share Attributable to Common Stockholders [Abstract]

Net Loss per Share Attributable to Common Stockholders

(14)	Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share:

	Three Months Ended March 31,
	2024			2023

Net loss attributable to common stockholders, basic & diluted	$	(3,599,510	)		(2,946,257	)

Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		21,775,357			11,872,255
Net loss per share attributable to common stockholders, basic and diluted	$	(0.17	)		(0.25	)

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

	March 31, 2024		March 31, 2023
Options to purchase common stock		2,998,233		1,036,495
Warrants to purchase common stock, in connection with April 2023 financing		68,809		—
Warrants to purchase common stock, in connection with November 2023 financing		11,610,166		—
Warrants to purchase common stock		201,578		233,460
Total potential shares		14,878,786		1,269,955

XML 32 R21.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2024

Income Taxes [Abstract]

Income Taxes [Text Block]

(15)	Income Taxes

The effective tax rate of 0% for the three months ended March 31, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

Subsequent Events

(16)	Subsequent Events

In April 2024, the Company sold 121,371 shares under the at-the-market facility, resulting in gross cash proceeds of $219,752.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 35 R24.htm IDEA: XBRL DOCUMENT

Organization, Nature of Business, and Liquidity (Policies)	3 Months Ended
	Mar. 31, 2024
Organization, Nature of Business, and Liquidity [Abstract]
Organization and Nature of Business	Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. The Company’s mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control. Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv® is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method and is approved for sale in the U.S. and Canada. FemCath®, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc®, the Company’s solution for permanent birth control, is based on the Company’s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
Liquidity	Liquidity As of March 31, 2024, the Company had cash and cash equivalents of $17,835,968. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the three months ended March 31, 2024, the Company generated a net loss of $3,599,510. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed. The Company believes that its cash and cash equivalents as of March 31, 2024 and cash received subsequent to quarter end (see Note 16, Subsequent Events) will be sufficient to fund our ongoing operations at least 12 months from the date of filing these condensed financial statements.
Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted	Recently Issued Accounting Pronouncements – Recently Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company’s financial statements and footnote disclosures. Recently Issued Accounting Pronouncements – Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2024

Inventories [Abstract]

Inventory Stated at Cost, Net of Reserve

Inventory stated at cost, net of reserve, consisted of the following:

	March 31,		December 31,
	2024		2023
Materials	$	574,199		367,934
Work in progress		131,657		128,993
Finished goods		265,441		170,191
Inventory, net	$	971,297		667,118

XML 37 R26.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2024

Accrued Expenses [Abstract]

Accrued Expenses

Accrued expenses consisted of the following:

	March 31,		December 31,
	2024		2023
Clinical trial costs	$	243,367		276,141
Accrued interest		147,275		—
Incentive and other compensation costs		146,409		1,082,606
Director fees		70,000		60,210
Franchise taxes		12,800		12,160
Other		53,606		13,179
Accrued expenses	$	673,457		1,444,296

XML 38 R27.htm IDEA: XBRL DOCUMENT

Clinical Holdback (Tables)

3 Months Ended

Mar. 31, 2024

Clinical Holdback [Abstract]

Clinical Holdback Liability

The following table shows the activity within the clinical holdback liability accounts for the three months ended March 31, 2024:

Balance at December 31, 2023	$	120,235
Clinical holdback retained		3,530
Clinical holdback paid		—
Balance at March 31, 2024	$	123,765
Less: clinical holdback - current portion		(93,376	)
Clinical holdback - long-term portion	$	30,389

XML 39 R28.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue Recognition [Abstract]

Sales by Geographic Region

The following table summarizes our sales, primarily from FemVue, by geographic region as follows:

	Three Months Ended March 31,
Primary geographical markets	2024		2023
U.S.	$	271,140		293,984
International		—		—
Total	$	271,140		293,984

XML 40 R29.htm IDEA: XBRL DOCUMENT

Convertible Notes with Warrants (November 2023 Financing) (Tables)

3 Months Ended

Mar. 31, 2024

Convertible Notes with Warrants (November 2023 Financing) [Abstract]

Fair Value Warrant and Black-Scholes Warrant Assumptions

The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:

	Series A Warrants			Series B Warrants
Expected term (in years)		5			1
Risk‑free interest rate		4.55	%		5.24	%
Dividend yield		—	%		—	%
Expected volatility		104.89	%		113.84	%
Exercise price	$	1.18		$	1.48
Stock price	$	0.95		$	0.95

Black-Scholes value	$	0.55		$	0.28

XML 41 R30.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants (Tables)

3 Months Ended

Mar. 31, 2024

Equity Incentive Plans and Warrants [Abstract]

Stock Option Plan Activity

Activity under the Company’s stock option plans for the three months ended March 31, 2024 was as follows:

	Number of options			Weighted average exercise price
Outstanding at December 31, 2023		2,102,030		$	2.00
Granted		708,821			0.97
Forfeited		(62,618	)		2.59
Outstanding at March 31, 2024		2,748,233		$	1.72

Vested and exercisable at March 31, 2024		1,208,627		$	2.63

Share-based Compensation Expense

	Three Months Ended March 31,
	2024		2023
Research and development	$	30,327		25,059
Sales and marketing		6,199		(2,544	)
General and administrative		41,059		34,439
Total share-based compensation expense	$	77,585		56,954

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Valuation Assumptions

	Pre-funded warrants			Common warrants
Expected term (in years)		4			4
Risk‑free interest rate		3.83	%		3.83	%
Dividend yield		—	%		—	%
Expected volatility		100.25	%		100.25	%
Exercise price	$	0.0001		$	1.095
Stock price	$	0.86		$	0.86
Black-Scholes value	$	0.86		$	0.58

2021 Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Estimated Using Assumptions

	Employee			Nonemployee
Expected term (in years)		6.25			1.50
Risk‑free interest rate		3.87	%		4.53	%
Dividend yield		—	%		—	%
Expected volatility		109.65	%		105.34	%

Inducement Grant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Estimated Using Assumptions

	Inducement
Expected term (in years)		6.25
Risk‑free interest rate		4.10	%
Dividend yield		—	%
Expected volatility		109.64	%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2024

Net Loss per Share Attributable to Common Stockholders [Abstract]

Computation of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the basic and diluted net loss per share:

	Three Months Ended March 31,
	2024			2023

Net loss attributable to common stockholders, basic & diluted	$	(3,599,510	)		(2,946,257	)

Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		21,775,357			11,872,255
Net loss per share attributable to common stockholders, basic and diluted	$	(0.17	)		(0.25	)

Computations of Diluted Weighted Average Shares Outstanding

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

	March 31, 2024		March 31, 2023
Options to purchase common stock		2,998,233		1,036,495
Warrants to purchase common stock, in connection with April 2023 financing		68,809		—
Warrants to purchase common stock, in connection with November 2023 financing		11,610,166		—
Warrants to purchase common stock		201,578		233,460
Total potential shares		14,878,786		1,269,955

XML 43 R32.htm IDEA: XBRL DOCUMENT

Organization, Nature of Business, and Liquidity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) Women Segment	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments \| Segment	1
Number of women used FemBloc for permanent birth control	401
Number of year where women's used for permanent birth control.	1 year
Number of women enrolled for a clinical readout	50
Number of women need to use for interim analysis of clinical data for permanent birth control	300
Period for analysis of clinical data for permanent birth control	1 year
Follow-up period for interim analysis of clinical data for permanent birth control	5 years
Liquidity [Abstract]
Cash and cash equivalents \| $	$ 17,835,968		$ 21,716,077
Net loss \| $	$ (3,599,510)	$ (2,946,257)

XML 44 R33.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Level 1 [Member] \| Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalent	$ 17,503,242	$ 21,278,895

XML 45 R34.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Inventories [Abstract]
Materials	$ 574,199	$ 367,934
Work in progress	131,657	128,993
Finished goods	265,441	170,191
Inventory, net	$ 971,297	$ 667,118

XML 46 R35.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accrued Expenses [Abstract]
Clinical trail costs	$ 243,367	$ 276,141
Accrued interest	147,275	0
Incentive and other compensation costs	146,409	1,082,606
Director fees	70,000	60,210
Franchise taxes	12,800	12,160
Other	53,606	13,179
Accrued expenses	$ 673,457	$ 1,444,296

XML 47 R36.htm IDEA: XBRL DOCUMENT

Clinical Holdback (Details) - USD ($)	3 Months Ended
Clinical Holdback (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Clinical Holdback Liability [Roll Forward]
Balance	$ 120,235
Clinical holdback retained	3,530
Clinical holdback paid	0
Balance	123,765
Less: clinical holdback - current portion	(93,376)	$ (65,300)
Clinical holdback - long-term portion	$ 30,389	$ 54,935

XML 48 R37.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Details) - USD ($)	3 Months Ended
Revenue Recognition (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Revenue Recognition [Abstract]
Revenue recognized from performance obligations in prior periods	$ 0	$ 0
Percentage of restocking fee	30.00%
Primary Geographical Markets [Abstract]
Sales	$ 271,140	293,984
FemVue [Member]
Primary Geographical Markets [Abstract]
Sales	271,140	293,984
FemVue [Member] \| U.S. [Member]
Primary Geographical Markets [Abstract]
Sales	271,140	293,984
FemVue [Member] \| International [Member]
Primary Geographical Markets [Abstract]
Sales	$ 0	$ 0
Minimum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term	30 days
Maximum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term	60 days

XML 49 R38.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - USD ($)	1 Months Ended		3 Months Ended
Notes Payable (Details) - USD ($)	Jul. 31, 2023	Jun. 30, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Notes Payable [Abstract]
Down payments			$ 0	$ 141,298
July Promissory Note [Member] \| AFCO Credit Corporation [Member]
Notes Payable [Abstract]
Proceeds to pay insurance premiums	$ 469,042
Down payments	$ 48,423
Interest rate	8.60%
Frequency of installment payments			monthly
Monthly principal and interest payments	$ 48,423
Maturity date of loan	Nov. 30, 2023
Note payable			$ 0		$ 0
Interest expense on loan			$ 0	$ 1,319
June Promissory Note [Member] \| AFCO Credit Corporation [Member]
Notes Payable [Abstract]
Proceeds to pay insurance premiums		$ 465,380
Down payments		$ 47,539
Interest rate		5.70%
Frequency of installment payments			monthly
Monthly principal and interest payments		$ 47,539
Maturity date of loan		Mar. 31, 2023

XML 50 R39.htm IDEA: XBRL DOCUMENT

Convertible Notes with Warrants (November 2023 Financing), Summary (Details) - November 2023 Financing [Member] - USD ($)		3 Months Ended
	Nov. 21, 2023	Mar. 31, 2024	Dec. 31, 2023
Convertible Notes [Abstract]
Proceeds from convertible notes	$ 6,850,000
Transaction costs	$ 525,144
Conversion price, period		18 months
Conversion price of common stock exceeds (in dollars per share)	$ 2.36
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Notes redeem at premium, percentage	115.00%
Series A Warrants [Member]
Convertible Notes [Abstract]
Warrants purchase shares of common stock (in shares)	5,805,083
Warrants exercise price (in dollars per share)	$ 1.18
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Series B Warrants [Member]
Convertible Notes [Abstract]
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Convertible Notes [Member]
Convertible Notes [Abstract]
Aggregate principal amount		$ 6,850,000	$ 6,850,000
Convertible note accrue interest rate		6.00%
Maturity date		Nov. 21, 2025
Convertible Notes [Member] \| Series B Warrants [Member]
Convertible Notes [Abstract]
Warrants purchase shares of common stock (in shares)	5,805,083
Warrants exercise price (in dollars per share)	$ 1.475
Convertible Notes [Member] \| Common Stock [Member]
Convertible Notes [Abstract]
Aggregate principal amount	$ 6,850,000
Conversion price (in dollars per share)	$ 1.18

XML 51 R40.htm IDEA: XBRL DOCUMENT

Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) - November 2023 Financing [Member]		3 Months Ended
	Nov. 21, 2023 USD ($)	Mar. 31, 2024 $ / shares
Warrants [Abstract]
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Proceeds from convertible notes	6,850,000
Transaction costs	525,144
Fair value of warrants	2,219,165
Debt discount	$ 2,744,309
Series A Warrants [Member]
Warrants [Abstract]
Percentage of warrant closing price of common stock exceeds	200.00%
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants term		5 years
Black-Scholes value (in dollars per share) \| $ / shares		$ 0.55
Series A Warrants [Member] \| Risk-free Interest Rate [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0.0455
Series A Warrants [Member] \| Dividend Yield [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0
Series A Warrants [Member] \| Expected Volatility [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		1.0489
Series A Warrants [Member] \| Exercise Price [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		1.18
Series A Warrants [Member] \| Stock Price [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0.95
Series B Warrants [Member]
Warrants [Abstract]
Percentage of warrant closing price of common stock exceeds	200.00%
Consecutive trading days		10 days
Daily dollar trading volume of common stock exceeds per day	$ 1,000,000
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants term		1 year
Black-Scholes value (in dollars per share) \| $ / shares		$ 0.28
Series B Warrants [Member] \| Risk-free Interest Rate [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0.0524
Series B Warrants [Member] \| Dividend Yield [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0
Series B Warrants [Member] \| Expected Volatility [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		1.1384
Series B Warrants [Member] \| Exercise Price [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		1.48
Series B Warrants [Member] \| Stock Price [Member]
Fair Value Method and Black-Scholes Assumptions [Abstract]
Warrants, measurement input		0.95

XML 52 R41.htm IDEA: XBRL DOCUMENT

Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Convertible Notes [Abstract]
Amortization of debt discount and issuance costs	$ 258,802	$ 0
Convertible Notes Payable [Abstract]
Accrued and unpaid interest	147,275		$ 0
November 2023 Financing [Member] \| Convertible Notes [Member]
Convertible Notes [Abstract]
Interest expense	361,552
Coupon interest expense	102,750
Amortization of debt discount and issuance costs	258,802
Convertible Notes Payable [Abstract]
Notes principal balance	6,850,000		6,850,000
Accrued and unpaid interest	147,275		44,525
Unamortized discount and debt issuance costs	2,377,544		$ 2,636,346
Convertible note, fair value	$ 6,185,934

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
Stockholders' Equity (Details) - USD ($)	Apr. 20, 2023	Apr. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Jul. 01, 2022
Stockholders Equity [Abstract]
Common stock sold (in shares)	1,318,000		3,900,000
Proceeds from Issuance of Common Stock			$ 802,242	$ 3,373	$ 8,700,000
Gross proceeds from offering	$ 3,899,813	$ 3,899,813
Placement agent fees expenses and offering expenses		$ 547,764
Common stock, outstanding (in shares)			22,099,347		22,099,347	21,657,381
Dividends declared or paid			$ 0
Maximum [Member]
Stockholders Equity [Abstract]
Authorized offering amount of securities								$ 150,000,000
Common stock authorized value to be issued by Sales Agent							$ 16,700,000
Pre-funded Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	1,878,722
Purchase price (in dollars per share)		$ 1.2199
Pre-funded Warrants [Member] \| Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		1,878,722
Common Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	3,196,722
Common Warrants [Member] \| Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		3,196,722
Placement Agent Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	191,803
Placement Agent Warrants [Member] \| Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		191,803
Common Stock [Member]
Stockholders Equity [Abstract]
Common stock sold (in shares)		1,318,000
Purchase price (in dollars per share)		$ 1.22

XML 54 R43.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) - 2021 Stock Option Plan [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Number of Options [Roll Forward]
Beginning balance (in shares) \| shares	2,102,030
Granted (in shares) \| shares	708,821
Forfeited (in shares) \| shares	(62,618)
Ending balance (in shares) \| shares	2,748,233
Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share) \| $ / shares	$ 2
Granted (in dollars per share) \| $ / shares	0.97
Forfeited (in dollars per share) \| $ / shares	2.59
Ending balance (in dollars per share) \| $ / shares	$ 1.72
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares) \| shares	1,208,627
Options vested and exercisable, Exercise price (in dollars per share) \| $ / shares	$ 2.63
Estimated Fair Value Assumptions [Abstract]
Options exercised (in shares) \| shares	0
Common stock reserved for issuance (in shares) \| shares	849,647
Employees [Member]
Number of Options [Roll Forward]
Granted (in shares) \| shares	706,321
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share) \| $ / shares	$ 0.97
Options vested and exercisable [Abstract]
Weighted-average fair values of options granted (in dollars per share) \| $ / shares	$ 0.83
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	6 years 3 months
Risk free interest rate	3.87%
Dividend yield	0.00%
Expected volatility	109.65%
Nonemployee [Member]
Number of Options [Roll Forward]
Granted (in shares) \| shares	2,500
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share) \| $ / shares	$ 0.79
Options vested and exercisable [Abstract]
Weighted-average fair values of options granted (in dollars per share) \| $ / shares	$ 0.39
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	1 year 6 months
Risk free interest rate	4.53%
Dividend yield	0.00%
Expected volatility	105.34%

XML 55 R44.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants, Inducement Grant (Details) - Inducement Grant [Member] - $ / shares	Feb. 12, 2024	Mar. 31, 2024
Inducement Grant [Abstract]
Granted (in shares)	100,000
Weighted average exercise price (in dollars per share)	$ 1.1	$ 1.89
Vesting period	4 years
Weighted-average fair values of options granted (in dollars per share)	$ 0.94
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	6 years 3 months
Risk free interest rate	4.10%
Dividend yield	0.00%
Expected volatility	109.64%
Shares outstanding (in shares)		250,000
Options vested and exercisable, Number of option vested (in shares)		62,500
Options vested and exercisable, Weighted average exercise price (in dollars per shares)		$ 2.64

XML 56 R45.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 77,585	$ 56,954
Share-based compensation expense expected to be recognized for employees and nonemployees	1,411,405
Compensation expense to be recognized upon achieving certain performance condition	155,222
Unrecognized expenses	$ 1,256,183
Weighted-average period over which unrecognized compensation is expected to be recognized	3 years 3 months 18 days
Research and Development [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 30,327	25,059
Sales and Marketing [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	6,199	(2,544)
General and Administrative [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 41,059	$ 34,439

XML 57 R46.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan [Member]	3 Months Ended
	Mar. 31, 2024 shares
Employee Stock Purchase Plan [Abstract]
Stock issued (in shares)	0
Common stock reserved for issuance (in shares)	603,518

XML 58 R47.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans and Warrants, April 2023 Financing (Details) - USD ($)		1 Months Ended			3 Months Ended
	Apr. 20, 2023	Oct. 31, 2023	Sep. 30, 2023	Apr. 30, 2023	Mar. 31, 2024
Warrants [Abstract]
Issuance and sale of common stock (in shares)	1,318,000				3,900,000
Gross proceeds from offering	$ 3,899,813			$ 3,899,813
Transaction costs	547,764
Common stock value	1,133,480
Estimated Fair Value Assumptions [Abstract]
Net proceeds from issuance of common stock and warrants	$ 3,352,049
Pre-funded Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	1,878,722
Warrants exercise price (In dollars per share)	$ 0.0001
Common stock value	$ 1,615,701
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	4 years
Risk free interest rate	3.83%
Dividend yield	0.00%
Expected volatility	100.25%
Exercise price (in dollars per share)	$ 0.0001
Stock price (in dollars per share)	0.86
Black-Scholes value (in dollars per share)	$ 0.86
Common Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	3,196,722
Warrants term					5 years 6 months
Warrants exercise price (In dollars per share)	$ 1.095
Common stock value	$ 1,854,099
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	4 years
Risk free interest rate	3.83%
Dividend yield	0.00%
Expected volatility	100.25%
Exercise price (in dollars per share)	$ 1.095
Stock price (in dollars per share)	0.86
Black-Scholes value (in dollars per share)	$ 0.58
Placement Agent Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	191,803
Warrants term					5 years
Warrants exercise price (In dollars per share)	$ 1.525
Estimated Fair Value Assumptions [Abstract]
Warrants exercised (in shares)		122,994	122,994
Cash proceeds from warrants exercised		$ 3,687,976	$ 3,687,976
Warrants outstanding (in shares)					68,809

XML 59 R48.htm IDEA: XBRL DOCUMENT

Related-Party Transactions (Details) $ in Millions	1 Months Ended
Related-Party Transactions (Details) $ in Millions	Nov. 30, 2023 USD ($)
Related-Party Transactions [Abstract]
Related-party transaction	$ 5

XML 60 R49.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss attributable to common stockholders, basic	$ (3,599,510)	$ (2,946,257)
Net loss attributable to common stockholders, diluted	$ (3,599,510)	$ (2,946,257)
Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares)	21,775,357	11,872,255
Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	21,775,357	11,872,255
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.17)	$ (0.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.17)	$ (0.25)
Weighted Average Number of Shares Outstanding [Abstract]
Options to purchase common stock (in shares)	2,998,233	1,036,495
Warrants to purchase common stock (in shares)	201,578	233,460
Total potential shares (in shares)	14,878,786	1,269,955
April 2023 Financing [Member]
Weighted Average Number of Shares Outstanding [Abstract]
Warrants to purchase common stock in connection financing (in shares)	68,809	0
November 2023 Financing [Member]
Weighted Average Number of Shares Outstanding [Abstract]
Warrants to purchase common stock in connection financing (in shares)	11,610,166	0

XML 61 R50.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	3 Months Ended
Income Taxes (Details)	Mar. 31, 2024	Mar. 31, 2023
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective tax rate	0.00%	0.00%

XML 62 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)		1 Months Ended
Subsequent Events (Details) - USD ($)	Apr. 20, 2023	Apr. 30, 2024
Issuance Sale of Common Stock [Abstract]
Gross cash proceeds from offering	$ 3,352,049
Subsequent Event [Member] \| At-the-Market Facility [Member]
Issuance Sale of Common Stock [Abstract]
Sale of common stock (in shares)		121,371
Gross cash proceeds from offering		$ 219,752

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 124 256 1 false 39 0 false 6 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://femasys.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - Condensed Balance Sheets Sheet http://femasys.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 010100 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://femasys.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - Condensed Statements of Comprehensive Loss Sheet http://femasys.com/role/CondensedStatementsOfComprehensiveLoss Condensed Statements of Comprehensive Loss Statements 4 false false R5.htm 030000 - Statement - Condensed Statements of Stockholders' Equity Sheet http://femasys.com/role/CondensedStatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity Statements 5 false false R6.htm 040000 - Statement - Condensed Statements of Cash Flows Sheet http://femasys.com/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 060100 - Disclosure - Organization, Nature of Business, and Liquidity Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity Organization, Nature of Business, and Liquidity Notes 7 false false R8.htm 060200 - Disclosure - Fair Value Sheet http://femasys.com/role/FairValue Fair Value Notes 8 false false R9.htm 060300 - Disclosure - Cash and Cash Equivalents Sheet http://femasys.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 060400 - Disclosure - Inventories Sheet http://femasys.com/role/Inventories Inventories Notes 10 false false R11.htm 060500 - Disclosure - Accrued Expenses Sheet http://femasys.com/role/AccruedExpenses Accrued Expenses Notes 11 false false R12.htm 060600 - Disclosure - Clinical Holdback Sheet http://femasys.com/role/ClinicalHoldback Clinical Holdback Notes 12 false false R13.htm 060700 - Disclosure - Revenue Recognition Sheet http://femasys.com/role/RevenueRecognition Revenue Recognition Notes 13 false false R14.htm 060800 - Disclosure - Commitments and Contingencies Sheet http://femasys.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 060900 - Disclosure - Notes Payable Notes http://femasys.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 061000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing Convertible Notes with Warrants (November 2023 Financing) Notes 16 false false R17.htm 061100 - Disclosure - Stockholders' Equity Sheet http://femasys.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 061200 - Disclosure - Equity Incentive Plans and Warrants Sheet http://femasys.com/role/EquityIncentivePlansAndWarrants Equity Incentive Plans and Warrants Notes 18 false false R19.htm 061300 - Disclosure - Related-Party Transactions Sheet http://femasys.com/role/RelatedpartyTransactions Related-Party Transactions Notes 19 false false R20.htm 061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 20 false false R21.htm 061500 - Disclosure - Income Taxes Sheet http://femasys.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 061600 - Disclosure - Subsequent Events Sheet http://femasys.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 061700 - Disclosure - Insider Trading Arrangements Sheet http://femasys.com/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 070100 - Disclosure - Organization, Nature of Business, and Liquidity (Policies) Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies Organization, Nature of Business, and Liquidity (Policies) Policies 24 false false R25.htm 080400 - Disclosure - Inventories (Tables) Sheet http://femasys.com/role/InventoriesTables Inventories (Tables) Tables http://femasys.com/role/Inventories 25 false false R26.htm 080500 - Disclosure - Accrued Expenses (Tables) Sheet http://femasys.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://femasys.com/role/AccruedExpenses 26 false false R27.htm 080600 - Disclosure - Clinical Holdback (Tables) Sheet http://femasys.com/role/ClinicalHoldbackTables Clinical Holdback (Tables) Tables http://femasys.com/role/ClinicalHoldback 27 false false R28.htm 080700 - Disclosure - Revenue Recognition (Tables) Sheet http://femasys.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://femasys.com/role/RevenueRecognition 28 false false R29.htm 081000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) (Tables) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables Convertible Notes with Warrants (November 2023 Financing) (Tables) Tables http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing 29 false false R30.htm 081200 - Disclosure - Equity Incentive Plans and Warrants (Tables) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsTables Equity Incentive Plans and Warrants (Tables) Tables http://femasys.com/role/EquityIncentivePlansAndWarrants 30 false false R31.htm 081400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders 31 false false R32.htm 090100 - Disclosure - Organization, Nature of Business, and Liquidity (Details) Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails Organization, Nature of Business, and Liquidity (Details) Details http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies 32 false false R33.htm 090300 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://femasys.com/role/CashAndCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://femasys.com/role/CashAndCashEquivalents 33 false false R34.htm 090400 - Disclosure - Inventories (Details) Sheet http://femasys.com/role/InventoriesDetails Inventories (Details) Details http://femasys.com/role/InventoriesTables 34 false false R35.htm 090500 - Disclosure - Accrued Expenses (Details) Sheet http://femasys.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://femasys.com/role/AccruedExpensesTables 35 false false R36.htm 090600 - Disclosure - Clinical Holdback (Details) Sheet http://femasys.com/role/ClinicalHoldbackDetails Clinical Holdback (Details) Details http://femasys.com/role/ClinicalHoldbackTables 36 false false R37.htm 090700 - Disclosure - Revenue Recognition (Details) Sheet http://femasys.com/role/RevenueRecognitionDetails Revenue Recognition (Details) Details http://femasys.com/role/RevenueRecognitionTables 37 false false R38.htm 090900 - Disclosure - Notes Payable (Details) Notes http://femasys.com/role/NotesPayableDetails Notes Payable (Details) Details http://femasys.com/role/NotesPayable 38 false false R39.htm 091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails Convertible Notes with Warrants (November 2023 Financing), Summary (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables 39 false false R40.htm 091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables 40 false false R41.htm 091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables 41 false false R42.htm 091100 - Disclosure - Stockholders' Equity (Details) Sheet http://femasys.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://femasys.com/role/StockholdersEquity 42 false false R43.htm 091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) Details 43 false false R44.htm 091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails Equity Incentive Plans and Warrants, Inducement Grant (Details) Details 44 false false R45.htm 091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) Details 45 false false R46.htm 091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) Details 46 false false R47.htm 091208 - Disclosure - Equity Incentive Plans and Warrants, April 2023 Financing (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails Equity Incentive Plans and Warrants, April 2023 Financing (Details) Details 47 false false R48.htm 091300 - Disclosure - Related-Party Transactions (Details) Sheet http://femasys.com/role/RelatedpartyTransactionsDetails Related-Party Transactions (Details) Details http://femasys.com/role/RelatedpartyTransactions 48 false false R49.htm 091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails Net Loss per Share Attributable to Common Stockholders (Details) Details http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables 49 false false R50.htm 091500 - Disclosure - Income Taxes (Details) Sheet http://femasys.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://femasys.com/role/IncomeTaxes 50 false false R51.htm 091600 - Disclosure - Subsequent Events (Details) Sheet http://femasys.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://femasys.com/role/SubsequentEvents 51 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName, us-gaap:DebtInstrumentMaturityDate - ef20026303_10q.htm 11 ef20026303_10q.htm femy-20240331.xsd femy-20240331_cal.xml femy-20240331_def.xml femy-20240331_lab.xml femy-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20026303_10q.htm": { "nsprefix": "femy", "nsuri": "http://femasys.com/20240331", "dts": { "inline": { "local": [ "ef20026303_10q.htm" ] }, "schema": { "local": [ "femy-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "femy-20240331_cal.xml" ] }, "definitionLink": { "local": [ "femy-20240331_def.xml" ] }, "labelLink": { "local": [ "femy-20240331_lab.xml" ] }, "presentationLink": { "local": [ "femy-20240331_pre.xml" ] } }, "keyStandard": 208, "keyCustom": 48, "axisStandard": 17, "axisCustom": 0, "memberStandard": 22, "memberCustom": 17, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 6, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 124, "entityCount": 1, "segmentCount": 39, "elementCount": 414, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 443, "http://xbrl.sec.gov/dei/2023": 31, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://femasys.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://femasys.com/role/CondensedBalanceSheets", "longName": "010000 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c20240331", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240331", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R3": { "role": "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "longName": "010100 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c20240331", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U003", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240331", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U003", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "longName": "020000 - Statement - Condensed Statements of Comprehensive Loss", "shortName": "Condensed Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R5": { "role": "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "longName": "030000 - Statement - Condensed Statements of Stockholders' Equity", "shortName": "Condensed Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://femasys.com/role/CondensedStatementsOfCashFlows", "longName": "040000 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:NetIncomeLoss", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:Depreciation", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R7": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity", "longName": "060100 - Disclosure - Organization, Nature of Business, and Liquidity", "shortName": "Organization, Nature of Business, and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://femasys.com/role/FairValue", "longName": "060200 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://femasys.com/role/CashAndCashEquivalents", "longName": "060300 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://femasys.com/role/Inventories", "longName": "060400 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://femasys.com/role/AccruedExpenses", "longName": "060500 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://femasys.com/role/ClinicalHoldback", "longName": "060600 - Disclosure - Clinical Holdback", "shortName": "Clinical Holdback", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ClinicalHoldbackTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ClinicalHoldbackTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://femasys.com/role/RevenueRecognition", "longName": "060700 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://femasys.com/role/CommitmentsAndContingencies", "longName": "060800 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://femasys.com/role/NotesPayable", "longName": "060900 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing", "longName": "061000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing)", "shortName": "Convertible Notes with Warrants (November 2023 Financing)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://femasys.com/role/StockholdersEquity", "longName": "061100 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrants", "longName": "061200 - Disclosure - Equity Incentive Plans and Warrants", "shortName": "Equity Incentive Plans and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://femasys.com/role/RelatedpartyTransactions", "longName": "061300 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders", "longName": "061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders", "shortName": "Net Loss per Share Attributable to Common Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://femasys.com/role/IncomeTaxes", "longName": "061500 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://femasys.com/role/SubsequentEvents", "longName": "061600 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://femasys.com/role/InsiderTradingArrangements", "longName": "061700 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies", "longName": "070100 - Disclosure - Organization, Nature of Business, and Liquidity (Policies)", "shortName": "Organization, Nature of Business, and Liquidity (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "femy:OrganizationAndNatureOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "femy:OrganizationAndNatureOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://femasys.com/role/InventoriesTables", "longName": "080400 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://femasys.com/role/AccruedExpensesTables", "longName": "080500 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://femasys.com/role/ClinicalHoldbackTables", "longName": "080600 - Disclosure - Clinical Holdback (Tables)", "shortName": "Clinical Holdback (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "femy:ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://femasys.com/role/RevenueRecognitionTables", "longName": "080700 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables", "longName": "081000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) (Tables)", "shortName": "Convertible Notes with Warrants (November 2023 Financing) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "femy:FairValueMethodAndBlackScholesAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "femy:FairValueMethodAndBlackScholesAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables", "longName": "081200 - Disclosure - Equity Incentive Plans and Warrants (Tables)", "shortName": "Equity Incentive Plans and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables", "longName": "081400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)", "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails", "longName": "090100 - Disclosure - Organization, Nature of Business, and Liquidity (Details)", "shortName": "Organization, Nature of Business, and Liquidity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U004", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U004", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://femasys.com/role/CashAndCashEquivalentsDetails", "longName": "090300 - Disclosure - Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c20240331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://femasys.com/role/InventoriesDetails", "longName": "090400 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c20240331", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240331", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://femasys.com/role/AccruedExpensesDetails", "longName": "090500 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c20240331", "name": "femy:AccruedClinicalTrialCost", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240331", "name": "femy:AccruedClinicalTrialCost", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://femasys.com/role/ClinicalHoldbackDetails", "longName": "090600 - Disclosure - Clinical Holdback (Details)", "shortName": "Clinical Holdback (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c20231231", "name": "femy:ClinicalHoldbackLiability", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231231", "name": "femy:ClinicalHoldbackLiability", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://femasys.com/role/RevenueRecognitionDetails", "longName": "090700 - Disclosure - Revenue Recognition (Details)", "shortName": "Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://femasys.com/role/NotesPayableDetails", "longName": "090900 - Disclosure - Notes Payable (Details)", "shortName": "Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:RepaymentsOfNotesPayable", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230701to20230731_DebtInstrumentAxis_JulyPromissoryNoteMember_LineOfCreditFacilityAxis_AFCOCreditCorporationMember", "name": "us-gaap:ProceedsFromNotesPayable", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R39": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "longName": "091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c20231121to20231121_DebtInstrumentAxis_November2023FinancingMember", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331_DebtInstrumentAxis_November2023FinancingMember", "name": "femy:PeriodOfConversionPrice", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R40": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "longName": "091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c20240101to20240331_DebtInstrumentAxis_November2023FinancingMember", "name": "femy:ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20231121to20231121_DebtInstrumentAxis_November2023FinancingMember", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R41": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "longName": "091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331_DebtInstrumentAxis_November2023FinancingMember_LongtermDebtTypeAxis_ConvertibleDebtMember", "name": "us-gaap:InterestExpenseDebt", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R42": { "role": "http://femasys.com/role/StockholdersEquityDetails", "longName": "091100 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c20230420to20230420", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230401to20230430", "name": "femy:PlacementAgentFeesExpensesAndOfferingExpenses", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R43": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "longName": "091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details)", "shortName": "Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c20231231_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_Two021StockOptionPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231231_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_Two021StockOptionPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "longName": "091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details)", "shortName": "Equity Incentive Plans and Warrants, Inducement Grant (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c20240212to20240212_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_InducementGrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240212to20240212_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_InducementGrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "longName": "091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details)", "shortName": "Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "longName": "091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details)", "shortName": "Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c20240101to20240331_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_EmployeeStockPurchasePlanMember", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_EmployeeStockPurchasePlanMember", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "longName": "091208 - Disclosure - Equity Incentive Plans and Warrants, April 2023 Financing (Details)", "shortName": "Equity Incentive Plans and Warrants, April 2023 Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c20230420to20230420", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230420to20230420", "name": "femy:PaymentsOfEquityIssuanceCosts", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R48": { "role": "http://femasys.com/role/RelatedpartyTransactionsDetails", "longName": "091300 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c20231101to20231130", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231101to20231130", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "longName": "091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } }, "R50": { "role": "http://femasys.com/role/IncomeTaxesDetails", "longName": "091500 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U006", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240331", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U006", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://femasys.com/role/SubsequentEventsDetails", "longName": "091600 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c20230420to20230420", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240401to20240430_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_AtTheMarketFacilityMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20026303_10q.htm", "unique": true } } }, "tag": { "femy_AFCOCreditCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "AFCOCreditCorporationMember", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "AFCO Credit Corporation, doing business as AFCO Insurance Premium Finance, provides premium financing services. The Company offers loans for businesses, finance property, and casualty insurance premiums. Afco Insurance Premium Finance serves clients worldwide.", "label": "AFCO Credit Corporation [Member]", "terseLabel": "AFCO Credit Corporation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://femasys.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16", "r571" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r217", "r218" ] }, "femy_AccruedClinicalTrialCost": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "AccruedClinicalTrialCost", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical trial cost.", "label": "Accrued Clinical Trial Cost", "terseLabel": "Clinical trail costs" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails", "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued expenses", "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r43", "r134", "r415" ] }, "femy_AcquisitionOfPatentsIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "AcquisitionOfPatentsIncludedInAccountsPayable", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of acquisition of patents included in accounts payable as a noncash or partial noncash transaction..", "label": "Acquisition of Patents Included in Accounts Payable", "terseLabel": "Acquisition of patents included in accounts payable" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r81", "r571", "r638" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r341", "r342", "r343", "r443", "r605", "r606", "r607", "r623", "r640" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r57", "r58", "r310" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r339", "r344" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs and discount", "terseLabel": "Amortization of debt discount and issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r263", "r386", "r556", "r557", "r601" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r40", "r41" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r115", "r136", "r159", "r201", "r207", "r211", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r357", "r359", "r377", "r409", "r480", "r571", "r584", "r616", "r617", "r627" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r130", "r142", "r159", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r357", "r359", "r377", "r571", "r616", "r617", "r627" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets, Fair Value Disclosure [Abstract]", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term assets", "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets." } } }, "auth_ref": [] }, "femy_AtTheMarketFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "AtTheMarketFacilityMember", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "An at-the-market (ATM) facility is a type of follow-on offering of stock utilized by publicly traded companies in order to raise capital over time.", "label": "At-the-Market Facility [Member]", "terseLabel": "At-the-Market Facility [Member]" } } }, "auth_ref": [] }, "femy_AuthorizedOfferingAmountOfSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "AuthorizedOfferingAmountOfSecurities", "crdr": "credit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The authorized offering amount of securities.", "label": "Authorized Offering Amount of Securities", "terseLabel": "Authorized offering amount of securities" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r33", "r132", "r547" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/CashAndCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r132", "r411" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalent", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r33", "r97", "r156" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r97" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents:" } } }, "auth_ref": [] }, "femy_CashPaidForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "CashPaidForAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Paid For [Abstract]", "terseLabel": "Cash paid for:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r127", "r137", "r138", "r139", "r159", "r179", "r184", "r191", "r193", "r199", "r200", "r219", "r232", "r234", "r235", "r236", "r239", "r240", "r272", "r273", "r276", "r279", "r286", "r377", "r434", "r435", "r436", "r437", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r468", "r489", "r510", "r526", "r527", "r528", "r529", "r530", "r594", "r602", "r608" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r137", "r138", "r139", "r199", "r272", "r273", "r274", "r276", "r279", "r284", "r286", "r434", "r435", "r436", "r437", "r558", "r594", "r602" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "http://femasys.com/role/StockholdersEquityDetails", "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r54" ] }, "femy_ClassOfWarrantOrRightBlackScholesValue": { "xbrltype": "perShareItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClassOfWarrantOrRightBlackScholesValue", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Black-Scholes value price per share or per unit of warrants.", "label": "Class of Warrant or Right, Black-Scholes Value", "terseLabel": "Black-Scholes value (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "http://femasys.com/role/StockholdersEquityDetails", "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price (in dollars per share)", "verboseLabel": "Warrants exercise price (In dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants purchase shares of common stock (in shares)", "terseLabel": "Warrants issued to purchase common stock (in shares)", "label": "Warrants issued to purchase common stock (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r54" ] }, "femy_ClinicalHoldbackAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackAbstract", "lang": { "en-us": { "role": { "label": "Clinical Holdback [Abstract]" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails", "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Clinical Holdback Current", "verboseLabel": "Clinical holdback - current portion", "negatedLabel": "Less: clinical holdback - current portion" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackLiability", "crdr": "credit", "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback liability.", "label": "Clinical Holdback Liability", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackLiabilityRollForward", "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails" ], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Clinical Holdback Liability [Roll Forward]", "terseLabel": "Clinical Holdback Liability [Roll Forward]" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackNoncurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails", "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback, due after one year or beyond the normal operating cycle, if longer.", "label": "Clinical Holdback, Noncurrent", "verboseLabel": "Clinical holdback - long-term portion" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackPaid", "crdr": "credit", "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing clinical holdback liability.", "label": "Clinical Holdback Paid", "negatedLabel": "Clinical holdback paid" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackRetained": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackRetained", "crdr": "debit", "presentation": [ "http://femasys.com/role/ClinicalHoldbackDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback retained during the period.", "label": "Clinical Holdback Retained", "terseLabel": "Clinical holdback retained" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "ClinicalHoldbackTextBlock", "presentation": [ "http://femasys.com/role/ClinicalHoldback" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of clinical holdback.", "label": "Clinical Holdback [Text Block]", "terseLabel": "Clinical Holdback" } } }, "auth_ref": [] }, "femy_CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of commission costs relating to certain proceeds from issuance of common stock incurred as a noncash or partial noncash transaction.", "label": "Commission Costs Relating to Certain Proceeds From Issuance of Common Stock", "terseLabel": "Commissions costs relating to certain proceeds from issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r25", "r68", "r410", "r467" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://femasys.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r104", "r226", "r227", "r533", "r613" ] }, "femy_CommonStockAuthorizedValueToBeIssuedBySalesAgent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "CommonStockAuthorizedValueToBeIssuedBySalesAgent", "crdr": "credit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock authorized value to be issued by Sales Agent to sell maximum shares at current market prices until all shares all sold.", "label": "Common Stock, Authorized Value to be Issued by Sales Agent", "terseLabel": "Common stock authorized value to be issued by Sales Agent" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r26" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r574", "r575", "r576", "r578", "r579", "r580", "r581", "r605", "r606", "r623", "r637", "r640" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r468" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r80", "r468", "r486", "r640", "r641" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r412", "r571" ] }, "femy_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "CommonWarrantsMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails", "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.", "label": "Common Warrants [Member]", "terseLabel": "Common Warrants [Member]" } } }, "auth_ref": [] }, "femy_ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The consecutive trading days, in which common stock exceeds the conversion price, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Consecutive Trading Days, Common Stock Exceeds the Conversion Price", "terseLabel": "Consecutive trading days" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Construction in progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r103" ] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized from performance obligations in prior periods", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r295" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note, fair value", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r106", "r242", "r243", "r253", "r254", "r255", "r259", "r260", "r261", "r262", "r263", "r553", "r554", "r555", "r556", "r557" ] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable, net (including related parties)", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r24" ] }, "femy_ConvertibleNotesWithWarrantsNovember2023FinancingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "ConvertibleNotesWithWarrantsNovember2023FinancingAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes with Warrants (November 2023 Financing) [Abstract]" } } }, "auth_ref": [] }, "femy_ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about convertible notes with warrants financing.", "label": "Convertible Notes with Warrants November 2023 Financing [Text Block]", "terseLabel": "Convertible Notes with Warrants (November 2023 Financing)" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of sales (excluding depreciation expense)", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r91", "r405" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "femy_DailyDollarTradingVolumeOfCommonStockExceedsPerDay": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "DailyDollarTradingVolumeOfCommonStockExceedsPerDay", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of daily dollar trading volume of the common stock exceeds per day during the same period and certain equity conditions.", "label": "Daily Dollar Trading Volume of Common Stock Exceeds per Day", "terseLabel": "Daily dollar trading volume of common stock exceeds per day" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r34", "r35" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://femasys.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r105", "r157", "r241", "r247", "r248", "r249", "r250", "r251", "r252", "r257", "r264", "r265", "r267" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r76", "r77", "r116", "r117", "r161", "r242", "r243", "r244", "r245", "r246", "r248", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r387", "r553", "r554", "r555", "r556", "r557", "r603" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate principal amount", "label": "Notes principal balance", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r14", "r117", "r268" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Conversion price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r107", "r244" ] }, "femy_DebtInstrumentConvertibleConversionPriceOfCommonStockExceeds": { "xbrltype": "perShareItemType", "nsuri": "http://femasys.com/20240331", "localname": "DebtInstrumentConvertibleConversionPriceOfCommonStockExceeds", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "The closing price per share of the common stock exceeds of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price of Common Stock Exceeds", "terseLabel": "Conversion price of common stock exceeds (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Frequency of installment payments", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": [ "r24", "r70" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible note accrue interest rate", "label": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r23", "r243" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r161", "r242", "r243", "r244", "r245", "r246", "r248", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r266", "r387", "r553", "r554", "r555", "r556", "r557", "r603" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date of loan", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r125", "r553", "r625" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r161", "r242", "r243", "r244", "r245", "r246", "r248", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r387", "r553", "r554", "r555", "r556", "r557", "r603" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Monthly principal and interest payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r24", "r70" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Notes redeem at premium, percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r48", "r51", "r63", "r64", "r66", "r69", "r109", "r110", "r161", "r242", "r243", "r244", "r245", "r246", "r248", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r266", "r387", "r553", "r554", "r555", "r556", "r557", "r603" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r63", "r66", "r619" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Unamortized discount and debt issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r65", "r253", "r269", "r554", "r555" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentsAbstract", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes [Abstract]", "terseLabel": "Notes Payable [Abstract]" } } }, "auth_ref": [] }, "femy_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of offering costs from noncash transactions included in deferred offering costs reclassified to additional paid-in-capital.", "label": "Deferred Offering Costs Reclassified to Additional Paid-In-Capital", "terseLabel": "Deferred offering costs reclassified to additional paid-in-capital" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r42" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r42" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueAbstract", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r299", "r559", "r560", "r561", "r562", "r563", "r564", "r565" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r299", "r559", "r560", "r561", "r562", "r563", "r564", "r565" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Expense", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r7", "r55" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Dividends declared or paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r3", "r111" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r588" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r589" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share Attributable to Common Stockholders [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "label": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r149", "r167", "r168", "r169", "r170", "r171", "r176", "r179", "r191", "r192", "r193", "r197", "r369", "r370", "r407", "r418", "r549" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "label": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r149", "r167", "r168", "r169", "r170", "r171", "r179", "r191", "r192", "r193", "r197", "r369", "r370", "r407", "r418", "r549" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders" ], "lang": { "en-us": { "role": { "label": "Net Loss per Share Attributable to Common Stockholders", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r175", "r194", "r195", "r196" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://femasys.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r347" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://femasys.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense expected to be recognized for employees and nonemployees", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r340" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average period over which unrecognized compensation is expected to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r340" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized expenses", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r622" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": [ "r59" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": [ "r60" ] }, "femy_EmployeeStockPurchasePlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "EmployeeStockPurchasePlanAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Abstract]", "terseLabel": "Employee Stock Purchase Plan [Abstract]" } } }, "auth_ref": [] }, "femy_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "documentation": "The Employee Stock Purchase Plan (the \"ESPP\") allows eligible full-time employees to purchase shares of common stock at 90 percent of the lower of the fair market value of a share of common stock on the first or last day of the quarter.", "label": "Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r586" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r586" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r593" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r586" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r592" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r586" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r586" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r586" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r586" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r128", "r145", "r146", "r147", "r162", "r163", "r164", "r166", "r172", "r174", "r198", "r220", "r221", "r288", "r341", "r342", "r343", "r351", "r352", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r378", "r379", "r380", "r381", "r382", "r383", "r390", "r426", "r427", "r428", "r443", "r510" ] }, "femy_EquityIncentivePlansAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "EquityIncentivePlansAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Equity Incentive Plans and Warrants [Abstract]" } } }, "auth_ref": [] }, "femy_EquityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "EquityWarrantsMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Equity Warrants [Member]", "terseLabel": "Warrants [Member]" } } }, "auth_ref": [] }, "femy_ExpirationOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ExpirationOfWarrant", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The warrants expired during the period.", "label": "Expiration of Warrant" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r5" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r372", "r373", "r376" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r372", "r373", "r376" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r61", "r62" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r255", "r302", "r303", "r304", "r305", "r306", "r307", "r373", "r400", "r401", "r402", "r554", "r555", "r566", "r567", "r568" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://femasys.com/role/FairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r371" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r255", "r302", "r307", "r373", "r400", "r566", "r567", "r568" ] }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsQuantitativeInformationAbstract", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Method and Black-Scholes Assumptions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r255", "r302", "r303", "r304", "r305", "r306", "r307", "r400", "r401", "r402", "r554", "r555", "r566", "r567", "r568" ] }, "femy_FairValueMethodAndBlackScholesAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "FairValueMethodAndBlackScholesAssumptionsTableTextBlock", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair Value Method and Black-Scholes Assumptions [Table Text Block]", "terseLabel": "Fair Value Warrant and Black-Scholes Warrant Assumptions" } } }, "auth_ref": [] }, "femy_FemVueMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "FemVueMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Pressure management device evaluates the women's fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study.", "label": "FemVue [Member]", "terseLabel": "FemVue [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments under lease obligations", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r388", "r389" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net of accumulated amortization", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r102", "r406" ] }, "femy_FollowUpPeriodForInterimAnalysisOfClinicalData": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "FollowUpPeriodForInterimAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Follow-up period for interim analysis of clinical data for permanent birth control", "label": "Follow-up Period for Interim Analysis of Clinical Data", "terseLabel": "Follow-up period for interim analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_FranchiseTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "FranchiseTaxes", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to franchise taxes.", "label": "Franchise Taxes", "terseLabel": "Franchise taxes" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r103" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r92", "r491" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r90" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "femy_IncentiveAndOtherCompensationCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "IncentiveAndOtherCompensationCostsCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to incentive and other compensation costs.", "label": "Incentive and Other Compensation Costs, Current", "terseLabel": "Incentive and other compensation costs" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Statements of Comprehensive Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r224", "r225", "r494" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r225", "r494" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://femasys.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r160", "r346", "r348", "r349", "r350", "r353", "r354", "r355", "r356", "r439" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r595", "r600" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid and other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": [ "r180", "r181", "r182", "r193" ] }, "femy_IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240331", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants", "calculation": { "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of pre-funded warrants, common warrants and placement agent warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Pre-Funded Warrants, Common Warrants and Placement Agent Warrants", "terseLabel": "Warrants to purchase common stock in connection financing (in shares)" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Options to purchase common stock (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r180", "r181", "r183", "r193", "r312" ] }, "femy_InducementGrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "InducementGrantAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Inducement Grant [Abstract]" } } }, "auth_ref": [] }, "femy_InducementGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "InducementGrantMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Inducement grants are a type of equity award to newly hired personnel.", "label": "Inducement Grant [Member]", "terseLabel": "Inducement Grant [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r590" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r65", "r120", "r148", "r204", "r385", "r495", "r582", "r639" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on loan", "verboseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r94", "r261", "r270", "r556", "r557" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Coupon interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r95", "r262", "r556", "r557" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r152", "r154", "r155" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "verboseLabel": "Accrued and unpaid interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://femasys.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r223" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://femasys.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r597" ] }, "us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory reserve write-off", "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period." } } }, "auth_ref": [ "r101" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://femasys.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, net", "totalLabel": "Inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r140", "r548", "r571" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://femasys.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r599" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://femasys.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Work in progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r598" ] }, "femy_JulyPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "JulyPromissoryNoteMember", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation in July of 2023.", "label": "July Promissory Note [Member]", "terseLabel": "July Promissory Note [Member]" } } }, "auth_ref": [] }, "femy_JunePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "JunePromissoryNoteMember", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation in June of 2022.", "label": "June Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r103" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r20", "r159", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r358", "r359", "r360", "r377", "r466", "r550", "r584", "r616", "r627", "r628" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r85", "r118", "r414", "r571", "r604", "r611", "r626" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r131", "r159", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r358", "r359", "r360", "r377", "r571", "r616", "r627", "r628" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r14", "r73", "r74", "r75", "r78", "r159", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r358", "r359", "r360", "r377", "r616", "r627", "r628" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r18", "r603" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r18", "r603" ] }, "femy_LiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "LiquidityAbstract", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity [Abstract]", "terseLabel": "Liquidity [Abstract]" } } }, "auth_ref": [] }, "femy_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the liquidity.", "label": "Liquidity [Policy Text Block]", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r44" ] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r103" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r308", "r404", "r425", "r458", "r459", "r517", "r519", "r521", "r522", "r524", "r543", "r544", "r552", "r558", "r569", "r573", "r618", "r629", "r630", "r631", "r632", "r633", "r634" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r624" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend Yield [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Expected Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r624" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r624" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r624" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r374" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r308", "r404", "r425", "r458", "r459", "r517", "r519", "r521", "r522", "r524", "r543", "r544", "r552", "r558", "r569", "r573", "r618", "r629", "r630", "r631", "r632", "r633", "r634" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r621" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r153" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r153" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r97", "r98", "r99" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r99", "r119", "r129", "r143", "r144", "r147", "r159", "r165", "r167", "r168", "r169", "r170", "r173", "r174", "r189", "r201", "r206", "r210", "r212", "r219", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r370", "r377", "r417", "r488", "r508", "r509", "r551", "r582", "r616" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to common stockholders, basic", "label": "Net loss attributable to common stockholders, basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r151", "r167", "r168", "r169", "r170", "r176", "r177", "r190", "r193", "r201", "r206", "r210", "r212", "r551" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to common stockholders, diluted", "label": "Net loss attributable to common stockholders, diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r151", "r178", "r185", "r186", "r187", "r188", "r190", "r193" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r591" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "International [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r642", "r643", "r644", "r645" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r19" ] }, "femy_November2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "November2023FinancingMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The November 2023 financing.", "label": "November 2023 Financing [Member]", "terseLabel": "November 2023 Financing [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r610" ] }, "femy_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240331", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Number of Warrants Exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "auth_ref": [] }, "femy_NumberOfWomenEnrolledForClinicalReadout": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240331", "localname": "NumberOfWomenEnrolledForClinicalReadout", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of additional women enrolled for a clinical readout.", "label": "Number of Women Enrolled for Clinical Readout", "terseLabel": "Number of women enrolled for a clinical readout" } } }, "auth_ref": [] }, "femy_NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240331", "localname": "NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of women need to use for interim analysis of clinical data for permanent birth control", "label": "Number of Women Need to Use for Interim Analysis of Clinical Data", "terseLabel": "Number of women need to use for interim analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_NumberOfWomenUsedFemBlocForPermanentBirthControl": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240331", "localname": "NumberOfWomenUsedFemBlocForPermanentBirthControl", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of women used FemBloc for permanent birth control", "label": "Number of Women Used FemBloc for Permanent Birth Control", "terseLabel": "Number of women used FemBloc for permanent birth control" } } }, "auth_ref": [] }, "femy_NumberOfYearWhereWomenSUsedForPermanentBirthControl": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "NumberOfYearWhereWomenSUsedForPermanentBirthControl", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of year where women's used for permanent birth control.", "label": "Number of Year Where Women's Used for Permanent Birth Control", "terseLabel": "Number of year where women's used for permanent birth control." } } }, "auth_ref": [] }, "femy_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.", "label": "Operating and Finance Lease, Liability, Current", "terseLabel": "Lease liabilities - current portion" } } }, "auth_ref": [] }, "femy_OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.", "label": "Operating and Finance Lease, Liability, Noncurrent", "verboseLabel": "Lease liabilities - long-term portion" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r201", "r206", "r210", "r212", "r551" ] }, "femy_OperatingLeaseAndFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "OperatingLeaseAndFinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of right-of-use asset from operating and finance lease.", "label": "Operating Lease and Finance Lease, Right-of-Use Asset", "terseLabel": "Lease right-of-use assets, net" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r601" ] }, "femy_OrganizationAndNatureOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "OrganizationAndNatureOfBusinessAbstract", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business [Abstract]", "terseLabel": "Organization and Nature of Business [Abstract]" } } }, "auth_ref": [] }, "femy_OrganizationAndNatureOfBusinessPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "OrganizationAndNatureOfBusinessPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the organization and nature of business.", "label": "Organization and Nature of Business [Policy Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Nature of Business, and Liquidity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity" ], "lang": { "en-us": { "role": { "terseLabel": "Organization, Nature of Business, and Liquidity", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r72", "r114", "r431", "r432" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://femasys.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r21" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid and other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r141", "r571" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r135" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs for at-the-market sales of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r30" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transaction costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r32" ] }, "femy_PaymentsOfEquityIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "PaymentsOfEquityIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Equity Issuance Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of patents", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r96" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r96" ] }, "femy_PercentageOfRestockingFee": { "xbrltype": "percentItemType", "nsuri": "http://femasys.com/20240331", "localname": "PercentageOfRestockingFee", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of restocking fee on items to be returned.", "label": "Percentage of Restocking Fee", "terseLabel": "Percentage of restocking fee" } } }, "auth_ref": [] }, "femy_PercentageOfWarrantClosingPriceOfCommonStockExceedsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://femasys.com/20240331", "localname": "PercentageOfWarrantClosingPriceOfCommonStockExceedsPercentage", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant has the right to call the exercise, if the closing price of the common stock exceeds.", "label": "Percentage of Warrant Closing Price of Common Stock Exceeds, Percentage", "terseLabel": "Percentage of warrant closing price of common stock exceeds" } } }, "auth_ref": [] }, "femy_PeriodForAnalysisOfClinicalData": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "PeriodForAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for analysis of clinical data for permanent birth control.", "label": "Period for analysis of clinical data", "terseLabel": "Period for analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_PeriodOfConversionPrice": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "PeriodOfConversionPrice", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of conversion price for a period after closing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Period of Conversion Price", "terseLabel": "Conversion price, period" } } }, "auth_ref": [] }, "femy_PlacementAgentFeesExpensesAndOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "PlacementAgentFeesExpensesAndOfferingExpenses", "crdr": "debit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of placement agent fees expense and offering expenses related to common stock and warrants.", "label": "Placement Agent Fees Expenses and Offering Expenses", "terseLabel": "Placement agent fees expenses and offering expenses" } } }, "auth_ref": [] }, "femy_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The member stands common stock issued to the placement agent as compensation for services (\"placement agent warrants\").", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "femy_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "PreFundedWarrantsMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "femy_PrimaryGeographicalMarketsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "PrimaryGeographicalMarketsAbstract", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Primary Geographical Markets [Abstract]", "terseLabel": "Primary Geographical Markets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible notes", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r29" ] }, "femy_ProceedsFromExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ProceedsFromExerciseOfCommonStockWarrants", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their common stock warrants.", "label": "Proceeds from Exercise of Common Stock Warrants", "verboseLabel": "Cash proceeds from warrants exercised" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from at-the-market sales of common stock", "verboseLabel": "Proceeds from Issuance of Common Stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from offering", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r434" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Sale of Common Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds to pay insurance premiums", "label": "Proceeds from Notes Payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r29" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r213", "r405", "r419", "r420", "r421", "r422", "r423", "r424", "r545", "r559", "r572", "r596", "r614", "r615", "r620", "r636" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r213", "r405", "r419", "r420", "r421", "r422", "r423", "r424", "r545", "r559", "r572", "r596", "r614", "r615", "r620", "r636" ] }, "femy_PropertyAndEquipmentCostsIncludedInAccountsPayableAndAccruedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "PropertyAndEquipmentCostsIncludedInAccountsPayableAndAccruedExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of property and equipment costs included in accounts payable and accrued expense as a noncash or partial noncash transaction.", "label": "Property and Equipment Costs, Included in Accounts Payable and Accrued Expense", "terseLabel": "Property and equipment costs included in accounts payable and accrued expense" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r103", "r133", "r416" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Net property and equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r408", "r416", "r571" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, at cost:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOther", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Property, Plant and Equipment, Other, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Provision for bad debts", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r150", "r222" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r301", "r308", "r335", "r336", "r337", "r403", "r404", "r425", "r458", "r459", "r517", "r519", "r521", "r522", "r524", "r543", "r544", "r552", "r558", "r569", "r573", "r576", "r612", "r618", "r630", "r631", "r632", "r633", "r634" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r301", "r308", "r335", "r336", "r337", "r403", "r404", "r425", "r458", "r459", "r517", "r519", "r521", "r522", "r524", "r543", "r544", "r552", "r558", "r569", "r573", "r576", "r612", "r618", "r630", "r631", "r632", "r633", "r634" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://femasys.com/role/RelatedpartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related-party transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r67", "r394" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/RelatedpartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related-Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r391", "r392", "r393", "r395", "r396", "r440", "r441", "r442", "r492", "r493", "r494", "r514", "r516" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of note payable", "terseLabel": "Down payments", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r71", "r345", "r635" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r82", "r111", "r413", "r429", "r430", "r438", "r469", "r571" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r128", "r162", "r163", "r164", "r166", "r172", "r174", "r220", "r221", "r341", "r342", "r343", "r351", "r352", "r361", "r363", "r364", "r366", "r368", "r426", "r428", "r443", "r640" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Sales", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r202", "r203", "r205", "r208", "r209", "r213", "r214", "r216", "r298", "r299", "r405" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://femasys.com/role/RevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r126", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r300" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://femasys.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Sales by Geographic Region", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r13" ] }, "femy_RevenueRecognitionPaymentTermOfPeriod": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240331", "localname": "RevenueRecognitionPaymentTermOfPeriod", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue recognition payment period term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Revenue Recognition, Payment Term of Period", "terseLabel": "Revenue recognition payment period term" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r591" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_SalariesWagesAndOfficersCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesWagesAndOfficersCompensationAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Expense [Abstract]", "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Gross cash proceeds from offering", "terseLabel": "Net proceeds from issuance of common stock and warrants", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of common stock (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Purchase price (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://femasys.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "femy_ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock", "presentation": [ "http://femasys.com/role/ClinicalHoldbackTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of clinical holdback liability account.", "label": "Schedule Of Clinical Holdback Liability Account [Table Text Block]", "terseLabel": "Clinical Holdback Liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables" ], "lang": { "en-us": { "role": { "label": "Computation of Basic and Diluted Net Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]", "documentation": "Describes the details pertaining to each employee stock ownership plan." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://femasys.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Inventory Stated at Cost, Net of Reserve", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r15", "r86", "r87", "r88" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Stock Option Plan Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r56" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Estimated Using Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r113" ] }, "femy_ScheduleOfShareBasedPaymentAwardFairValueWarrantLiabilityValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240331", "localname": "ScheduleOfShareBasedPaymentAwardFairValueWarrantLiabilityValuationAssumptionsTableTextBlock", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share Based Payment Award, Fair Value Warrant Liability, Valuation Assumptions [Table Text Block]", "terseLabel": "Warrants Valuation Assumptions" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r109", "r110", "r111", "r137", "r138", "r139", "r199", "r272", "r273", "r274", "r276", "r279", "r284", "r286", "r434", "r435", "r436", "r437", "r558", "r594", "r602" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables" ], "lang": { "en-us": { "role": { "label": "Computations of Diluted Weighted Average Shares Outstanding", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r36" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r585" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r587" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r214", "r215", "r455", "r456", "r457", "r518", "r520", "r523", "r525", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r546", "r560", "r576", "r620", "r636" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Sales and Marketing [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r90" ] }, "femy_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "SeriesAWarrantsMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "A classification of Information by type of warrant or right issued, for example Series A Warrants.", "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants [Member]" } } }, "auth_ref": [] }, "femy_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "SeriesBWarrantsMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "A classification of Information by type of warrant or right issued, for example Series B Warrants.", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r570" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Estimated Fair Value Assumptions [Abstract]", "terseLabel": "Estimated Fair Value Assumptions [Abstract]" } } }, "auth_ref": [] }, "femy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesValue": { "xbrltype": "perShareItemType", "nsuri": "http://femasys.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesValue", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company under Black-Scholes assumptions.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Black-Scholes Value", "terseLabel": "Black-Scholes value (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r336" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r337" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r322" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average fair values of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r330" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options vested and exercisable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options vested and exercisable, Number of option vested (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options vested and exercisable, Weighted average exercise price (in dollars per shares)", "label": "Options vested and exercisable, Exercise price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r322" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r320" ] }, "femy_ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement to be recognized upon achieving certain performance condition.", "label": "Share-based Compensation Expense to be Recognized upon Achieving Certain Performance Condition", "terseLabel": "Compensation expense to be recognized upon achieving certain performance condition" } } }, "auth_ref": [] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Employees [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r309", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r334" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans and Warrants", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r108", "r112" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r127", "r137", "r138", "r139", "r159", "r179", "r184", "r191", "r193", "r199", "r200", "r219", "r232", "r234", "r235", "r236", "r239", "r240", "r272", "r273", "r276", "r279", "r286", "r377", "r434", "r435", "r436", "r437", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r468", "r489", "r510", "r526", "r527", "r528", "r529", "r530", "r594", "r602", "r608" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r27", "r128", "r145", "r146", "r147", "r162", "r163", "r164", "r166", "r172", "r174", "r198", "r220", "r221", "r288", "r341", "r342", "r343", "r351", "r352", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r378", "r379", "r380", "r381", "r382", "r383", "r390", "r426", "r427", "r428", "r443", "r510" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r214", "r215", "r455", "r456", "r457", "r518", "r520", "r523", "r525", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r546", "r560", "r576", "r620", "r636" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r162", "r163", "r164", "r198", "r405", "r433", "r454", "r460", "r461", "r462", "r463", "r464", "r465", "r468", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r485", "r487", "r490", "r491", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r577" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statements of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r162", "r163", "r164", "r198", "r405", "r433", "r454", "r460", "r461", "r462", "r463", "r464", "r465", "r468", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r485", "r487", "r490", "r491", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r577" ] }, "femy_StockBasedCompensationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "StockBasedCompensationExpenseAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation Expense [Abstract]", "terseLabel": "Share-based Compensation Expense [Abstract]" } } }, "auth_ref": [] }, "femy_StockIssuedDuringPeriodSharesAtTheMarketOfferingNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240331", "localname": "StockIssuedDuringPeriodSharesAtTheMarketOfferingNetOfIssuanceCosts", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued in connection with the at-the-market program during the period.", "label": "Stock Issued During Period, Shares, At-The-Market Offering, Net of issuance Costs", "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Stock issued (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r8", "r79", "r80", "r111" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance and sale of common stock (in shares)", "label": "Common stock sold (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r79", "r80", "r111", "r434", "r510", "r527" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r79", "r80", "r111", "r321" ] }, "femy_StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240331", "localname": "StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued in connection with at-the-market program during the period.", "label": "Stock Issued During Period, Value, At-The-Market Offering, Net of Issuance Costs", "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r79", "r80", "r111", "r443", "r510", "r527", "r583" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r80", "r83", "r84", "r100", "r470", "r486", "r511", "r512", "r571", "r584", "r604", "r611", "r626", "r640" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://femasys.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r108", "r158", "r271", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r288", "r367", "r513", "r515", "r531" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r384", "r398" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r384", "r398" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r384", "r398" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r384", "r398" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r384", "r398" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://femasys.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r397", "r399" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://femasys.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Common Stock [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury stock, common shares (in shares)", "periodStartLabel": "Treasury stock, common shares (in shares)", "periodEndLabel": "Treasury stock, common shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, 117,223 common shares", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r28", "r52", "r53" ] }, "femy_Two021StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "Two021StockOptionPlanMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Name of the stock-based compensation arrangement option plan.", "label": "2021 Stock Option Plan [Member]", "terseLabel": "2021 Stock Option Plan [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "U.S. [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r37", "r38", "r39", "r121", "r122", "r123", "r124" ] }, "femy_WarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "WarrantsAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://femasys.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants, measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r375" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants term", "label": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r625" ] }, "femy_WarrantsSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "WarrantsSevenMember", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights represent derivative securities that give the holder the right to purchase securities.", "label": "Warrants Seven [Member]", "terseLabel": "November 2023 Financing [Member]" } } }, "auth_ref": [] }, "femy_WarrantsSixMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240331", "localname": "WarrantsSixMember", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights represent derivative securities that give the holder the right to purchase securities.", "label": "Warrants Six [Member]", "terseLabel": "April 2023 Financing [Member]" } } }, "auth_ref": [] }, "femy_WarrantsTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240331", "localname": "WarrantsTransactionsAbstract", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Transactions [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total potential shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r609" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "label": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r178", "r193" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "label": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r176", "r193" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r594": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 71 0001140361-24-025068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-025068-xbrl.zip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end XML 73 ef20026303_10q_htm.xml IDEA: XBRL DOCUMENT 0001339005 2024-01-01 2024-03-31 0001339005 2024-05-08 0001339005 2023-12-31 0001339005 2024-03-31 0001339005 2023-01-01 2023-03-31 0001339005 us-gaap:CommonStockMember 2023-12-31 0001339005 femy:EquityWarrantsMember 2022-12-31 0001339005 2022-12-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001339005 us-gaap:TreasuryStockCommonMember 2023-12-31 0001339005 femy:EquityWarrantsMember 2023-12-31 0001339005 us-gaap:RetainedEarningsMember 2022-12-31 0001339005 us-gaap:RetainedEarningsMember 2023-12-31 0001339005 us-gaap:TreasuryStockCommonMember 2022-12-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001339005 us-gaap:CommonStockMember 2022-12-31 0001339005 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001339005 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001339005 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001339005 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001339005 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001339005 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001339005 femy:EquityWarrantsMember 2024-01-01 2024-03-31 0001339005 femy:EquityWarrantsMember 2023-01-01 2023-03-31 0001339005 us-gaap:TreasuryStockCommonMember 2023-03-31 0001339005 us-gaap:TreasuryStockCommonMember 2024-03-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001339005 femy:EquityWarrantsMember 2024-03-31 0001339005 femy:EquityWarrantsMember 2023-03-31 0001339005 2023-03-31 0001339005 us-gaap:RetainedEarningsMember 2024-03-31 0001339005 us-gaap:RetainedEarningsMember 2023-03-31 0001339005 us-gaap:CommonStockMember 2023-03-31 0001339005 us-gaap:CommonStockMember 2024-03-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001339005 femy:InducementGrantMember 2024-01-01 2024-03-31 0001339005 femy:Two021StockOptionPlanMember 2024-01-01 2024-03-31 0001339005 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001339005 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001339005 srt:MinimumMember 2024-01-01 2024-03-31 0001339005 srt:MaximumMember 2024-01-01 2024-03-31 0001339005 femy:FemVueMember 2024-01-01 2024-03-31 0001339005 femy:FemVueMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0001339005 femy:FemVueMember country:US 2023-01-01 2023-03-31 0001339005 femy:FemVueMember us-gaap:NonUsMember 2024-01-01 2024-03-31 0001339005 femy:FemVueMember country:US 2024-01-01 2024-03-31 0001339005 femy:FemVueMember 2023-01-01 2023-03-31 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2022-06-01 2022-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-07-01 2023-07-31 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2022-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-07-31 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2024-01-01 2024-03-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2024-01-01 2024-03-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-12-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2024-03-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-01-01 2023-03-31 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember femy:SeriesBWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-03-31 0001339005 femy:November2023FinancingMember 2024-01-01 2024-03-31 0001339005 femy:November2023FinancingMember 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2024-01-01 2024-03-31 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2024-01-01 2024-03-31 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputExpectedDividendRateMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputRiskFreeInterestRateMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputExpectedDividendRateMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputSharePriceMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputRiskFreeInterestRateMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputExercisePriceMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputSharePriceMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputPriceVolatilityMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputExercisePriceMember femy:SeriesBWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:MeasurementInputPriceVolatilityMember femy:SeriesAWarrantsMember 2024-03-31 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2023-12-31 0001339005 srt:MaximumMember 2022-07-01 0001339005 srt:MaximumMember 2023-10-31 0001339005 us-gaap:CommonStockMember 2023-04-01 2023-04-30 0001339005 2023-10-01 2024-03-31 0001339005 srt:MaximumMember femy:PreFundedWarrantsMember 2023-04-30 0001339005 srt:MaximumMember femy:PlacementAgentWarrantsMember 2023-04-30 0001339005 srt:MaximumMember femy:CommonWarrantsMember 2023-04-30 0001339005 femy:PreFundedWarrantsMember 2023-04-30 0001339005 us-gaap:CommonStockMember 2023-04-30 0001339005 2023-04-01 2023-04-30 0001339005 femy:Two021StockOptionPlanMember 2023-12-31 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-03-31 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-03-31 0001339005 femy:Two021StockOptionPlanMember 2024-03-31 0001339005 femy:InducementGrantMember 2024-02-12 2024-02-12 0001339005 femy:InducementGrantMember 2024-02-12 0001339005 femy:InducementGrantMember 2024-03-31 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001339005 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001339005 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001339005 femy:EmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001339005 femy:EmployeeStockPurchasePlanMember 2024-03-31 0001339005 2023-04-20 2023-04-20 0001339005 femy:CommonWarrantsMember 2023-04-20 0001339005 femy:PreFundedWarrantsMember 2023-04-20 0001339005 femy:PlacementAgentWarrantsMember 2023-04-20 0001339005 femy:CommonWarrantsMember 2024-03-31 0001339005 femy:PlacementAgentWarrantsMember 2024-03-31 0001339005 femy:CommonWarrantsMember 2023-04-20 2023-04-20 0001339005 femy:PreFundedWarrantsMember 2023-04-20 2023-04-20 0001339005 femy:PlacementAgentWarrantsMember 2023-10-01 2023-10-31 0001339005 femy:PlacementAgentWarrantsMember 2023-09-01 2023-09-30 0001339005 2023-11-01 2023-11-30 0001339005 femy:WarrantsSixMember 2023-01-01 2023-03-31 0001339005 femy:WarrantsSevenMember 2023-01-01 2023-03-31 0001339005 femy:WarrantsSevenMember 2024-01-01 2024-03-31 0001339005 femy:WarrantsSixMember 2024-01-01 2024-03-31 0001339005 us-gaap:SubsequentEventMember femy:AtTheMarketFacilityMember 2024-04-01 2024-04-30 shares iso4217:USD iso4217:USD shares femy:Segment femy:Women pure false --12-31 2024 Q1 0001339005 2023-03-31 NASDAQ 2023-11-30 10-Q true 2024-03-31 false 001-40492 Femasys Inc. DE 11-3713499 3950 Johns Creek Court Suite 100 Suwanee GA 30024 770 500-3910 Common stock, $0.001 par value FEMY Yes Yes Non-accelerated Filer true true true false 22220718 17835968 21716077 120529 98906 971297 667118 955539 695879 19883333 23177980 1212417 1212417 47308 47308 417654 414303 2582220 2559356 569723 423077 4829322 4656461 3615405 3545422 1213917 1111039 2227561 2380225 33115 0 1013034 1086581 3273710 3466806 24370960 27755825 1095730 1137823 673457 1444296 93376 65300 494967 406636 2357530 3054055 30389 54935 4472456 4258179 1902991 2036067 6405836 6349181 8763366 9403236 0.001 0.001 200000000 200000000 22216570 22099347 21774604 21657381 22217 21775 117223 117223 60000 60000 2631838 2787137 124994678 123985306 -111981139 -108381629 15607594 18352589 24370960 27755825 271140 293984 88532 105120 1770731 1537439 300487 244896 1502804 1315137 71228 133066 3645250 3230538 -3462642 -3041674 224684 97089 361552 1672 -136868 95417 -3599510 -2946257 -3599510 -3599510 -2946257 -2946257 -0.17 -0.17 -0.25 -0.25 21775357 21775357 11872255 11872255 21774604 21775 117223 -60000 2787137 123985306 -108381629 18352589 0 0 0 77585 0 77585 441966 442 0 0 0 776488 0 776930 -155299 155299 0 0 0 0 -3599510 -3599510 22216570 22217 117223 -60000 2631838 124994678 -111981139 15607594 11986927 11987 117223 -60000 567972 108857065 -94134505 15242519 2869 3 0 0 0 3365 0 3368 0 0 0 56954 0 56954 0 0 0 0 -2946257 -2946257 11989796 11990 117223 -60000 567972 108917384 -97080762 12356584 -3599510 -2946257 69983 131653 1245 1413 152664 75635 1000 0 1240 300 77585 56954 258802 0 22623 46485 305419 64318 187359 -150654 -137753 3016 -792239 78703 -44745 -91211 -40995 2306 -4568124 -2647637 25603 0 64557 8901 -90160 -8901 802242 3373 24067 0 0 141298 0 6135 778175 -144060 -3880109 -2800598 21716077 12961936 17835968 10161338 0 1672 108304 12990 8757 0 109 1245 0 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(1)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Organization, Nature of Business, and Liquidity</div> </td> </tr> </table> </div> <div> </div> <div style="margin-right: 154.8pt; font-style: italic; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">Organization and Nature of Business</div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company’s mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company currently operates a</span>s one </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.</span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> <br/> </div> <div style="margin-top: 0px; margin-bottom: 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: left; text-transform: none; background-color: rgb(255, 255, 255); font-variant: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv® is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method and is approved for sale in the U.S. and Canada. FemCath®, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">®</span>, the Company’s solution for permanent birth control, is based on the Company’s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.</span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Basis of Presentation</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: normal;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">The <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report.</span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">In <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.</span></div> <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="font-style: italic;">Use of Estimates</span></span><br/> </div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-style: italic;"> <br/> </span></div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">The <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.</span></div> <div><br/> </div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Liquidity</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of March 31, 2024, the Company had cash and cash equivalents of </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> $17,835,968. <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted.</span></span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the three months ended March 31, 2024, the Company generated a net loss of</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> $3,599,510. <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed.</span></span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company believes that its cash and cash equivalents as of March 31, 2024 and cash received subsequent to quarter end (see Note 16</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">Subsequent Events</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">) will be sufficient to fund our ongoing operations at least 12 months from the date of filing these condensed financial statements.</span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><br/> </div> <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Recently Adopted</span><br/> <br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0);">I</span>n November 2023, the FASB issued ASU No. 2023-07, <span style="font-style: italic;">Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures</span>. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company’s financial statements and footnote disclosures.</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Not Yet Adopted</div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </div> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025.</span> </div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">No <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.</span></div> <div style="margin-right: 154.8pt; font-style: italic; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">Organization and Nature of Business</div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company’s mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company currently operates a</span>s one </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.</span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> <br/> </div> <div style="margin-top: 0px; margin-bottom: 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: left; text-transform: none; background-color: rgb(255, 255, 255); font-variant: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv® is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method and is approved for sale in the U.S. and Canada. FemCath®, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">®</span>, the Company’s solution for permanent birth control, is based on the Company’s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.</span></div> 1 401 P1Y 50 300 P1Y P5Y <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Basis of Presentation</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: normal;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">The <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report.</span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">In <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.</span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="font-style: italic;">Use of Estimates</span></span><br/> </div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-style: italic;"> <br/> </span></div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">The <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.</span></div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Liquidity</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of March 31, 2024, the Company had cash and cash equivalents of </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> $17,835,968. <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted.</span></span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"> </span> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the three months ended March 31, 2024, the Company generated a net loss of</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> $3,599,510. <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed.</span></span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company believes that its cash and cash equivalents as of March 31, 2024 and cash received subsequent to quarter end (see Note 16</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">Subsequent Events</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">) will be sufficient to fund our ongoing operations at least 12 months from the date of filing these condensed financial statements.</span></div> 17835968 -3599510 <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Recently Adopted</span><br/> <br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0);">I</span>n November 2023, the FASB issued ASU No. 2023-07, <span style="font-style: italic;">Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures</span>. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company’s financial statements and footnote disclosures.</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Not Yet Adopted</div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </div> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025.</span> </div> <div style="margin-right: 36pt; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">No <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.</span></div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(2)</div> </td> <td style="text-align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value<br/> </div> </td> </tr> </table> </div> <div><br/> </div> <div>The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: </div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model‑based valuation techniques for which all significant assumptions are observable in the market.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Level 3 – Valuation is generated from model‑based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the asset or liability.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Certain of the Company’s financial instruments, including cash and cash equivalents, notes payable and other liabilities approximate their fair value because of the short‑term maturity of these financial instruments and are based on Level 1 inputs. The Company’s equity-classified warrants and stock options are measured at fair value upon grant using the Black-Scholes option pricing model, a Level 2 input. The Company uses unobservable inputs for the model’s assumptions, including management’s assumptions of the Company’s volatility and price of the underlying stock. The fair value of the Company’s convertible notes is disclosed at each reporting period based on a discounted cash flow analysis, a Level 3 input.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(3)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Cash and Cash Equivalents</div> </td> </tr> </table> </div> <div> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of March 31, 2024 and December 31, 2023, money market funds included in cash and cash equivalents on the balance sheets were $17,503,242 and $21,278,895, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets.</div> 17503242 21278895 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(4)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Inventories</div> </td> </tr> </table> </div> <div> </div> <div style="margin-right: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Inventory stated at cost, net of reserve, consisted of the following:</div> <div><br/></div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">March 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2023<br/> </span> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Materials</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">574,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">367,934</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Work in progress</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">131,657</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">128,993</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Finished goods</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">265,441</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">170,191</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Inventory, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">971,297</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">667,118</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="margin-right: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Inventory stated at cost, net of reserve, consisted of the following:</div> <div><br/></div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">March 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2023<br/> </span> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Materials</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">574,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">367,934</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Work in progress</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">131,657</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">128,993</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Finished goods</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">265,441</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">170,191</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Inventory, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">971,297</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">667,118</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 574199 367934 131657 128993 265441 170191 971297 667118 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(5)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Accrued Expenses</div> </td> </tr> </table> </div> <div> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">March 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;"> 2024</span><br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2023<br/> </td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical trial costs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">243,367</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">276,141</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">147,275</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Incentive and other compensation costs<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">146,409</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,082,606</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Director fees </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">70,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">60,210</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Franchise taxes <br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,800</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,160</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>53,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,179</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Accrued expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">673,457</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,444,296</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">March 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;"> 2024</span><br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2023<br/> </td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical trial costs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">243,367</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">276,141</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">147,275</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Incentive and other compensation costs<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">146,409</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,082,606</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Director fees </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">70,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">60,210</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Franchise taxes <br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,800</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,160</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>53,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,179</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Accrued expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">673,457</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,444,296</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 243367 276141 147275 0 146409 1082606 70000 60210 12800 12160 53606 13179 673457 1444296 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(6)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Clinical Holdback</div> </td> </tr> </table> </div> <div> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the activity within the clinical holdback liability accounts for the three months ended March 31, 2024:</div> <div> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, 2023<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">120,235</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback retained</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3,530</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback paid</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at March 31, 2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">123,765</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Less: clinical holdback - current portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>(93,376</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback - long-term portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div>30,389</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the activity within the clinical holdback liability accounts for the three months ended March 31, 2024:</div> <div> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, 2023<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">120,235</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback retained</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3,530</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback paid</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at March 31, 2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">123,765</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Less: clinical holdback - current portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>(93,376</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback - long-term portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div>30,389</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 120235 3530 0 123765 93376 30389 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(7)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Revenue Recognition</div> </td> </tr> </table> </div> <div> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three months ended March 31, 2024 and 2023, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of March 31, 2024 or 2023.</div> <div><br/></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns.</div> <div> <br/> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table summarizes our sales, primarily from FemVue, by geographic region as follows:</div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Primary geographical markets</span> <br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">U.S.</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">271,140</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">293,984</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">International</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">271,140</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">293,984</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> </div> </td> </tr> </table> P30D P60D 0 0 0.30 <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table summarizes our sales, primarily from FemVue, by geographic region as follows:</div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Primary geographical markets</span> <br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">U.S.</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">271,140</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">293,984</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">International</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 68.12%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.92%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">271,140</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.64%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">293,984</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> </div> </td> </tr> </table> 271140 293984 0 0 271140 293984 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(8)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Commitments and Contingencies</div> </td> </tr> </table> </div> <div><br/> </div> <div style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Legal Claims</div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Accounting Standards Codification</span> (ASC) 450, <span style="font-style: italic;">Contingencies</span>, the Company will assess the likelihood of an adverse judgment for any outstanding claim as well as ranges of probable losses. When it has been determined that a loss is probable and the amount can be reasonably estimated, the Company will record a liability. For both periods presented, there were no material legal contingencies requiring accrual or disclosure.</div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of March 31, 2024 and December 31, 2023.</div> <div> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(9)</div> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Notes Payable</div> </td> </tr> </table> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-style: normal; margin-right: 154.8pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;">AFCO Credit Corporation (AFCO)</span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In June 2022, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate was 5.7% and the monthly installment payment was $47,539, which represents principal and interest. The final installment payment was paid in <span style="-sec-ix-hidden:Fact_1094516f8ffb4539a3f7695a375217e7">March of 2023</span>.</div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/> </span></div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In July 2023, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate was 8.6% and the monthly installment is $48,423, which represents principal and interest.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> The Promissory Note was paid in full without penalty in <span style="-sec-ix-hidden:Fact_695e21fc4ca04ba68cb802a57d87ac67">November 2023</span></span>.</div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of March </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span>2024,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span>2023,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> there was no principal balance on the AFCO note in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was </span>$0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>$1,319<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the </span>three<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> months ended March </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span>2024<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2023,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> respectively.</span></div> 465380 47539 0.057 monthly 47539 469042 48423 0.086 monthly 48423 0 0 0 1319 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">(10)</div> </td> <td style="text-align: left; vertical-align: top; width: auto;"> <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Convertible Notes with Warrants (November 2023 Financing)</div> </td> </tr> </table> </div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs. The Company intends to use the net proceeds from the offering for general corporate purposes.</span></div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Company’s option, and mature on November 21, 2025, unless earlier converted or redeemed.</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holder’s Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of March 31, 2024, the Convertible Notes have not been converted into shares of common stock.<br/> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"> <br/> </div> <div><span style="font-style: italic;">The Warrants </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied.</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Series B Warrants are exercisable immediately, together with the Series A Warrant Shares, and expire one year from the date of issuance. The Company has the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeds 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system.</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Series A</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Warrants</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Series B</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Warrants</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Expected term (in years)</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Risk‑free interest rate</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">4.55</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5.24</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Dividend yield</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Expected volatility</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">104.89</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">113.84</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Exercise price</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1.18</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1.48</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Stock price</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.95</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.95</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="margin-left: 9pt; text-indent: -9pt;"> </div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Black-Scholes value</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.55</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.28</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The November 2023 Financing proceeds of $6,850,000 net of $525,144 in transaction costs were allocated to the convertible notes and Series A and Series B Warrants using the relative fair value method. The valuation of the warrants was $2,219,165 and was recorded as a component of stockholders’ equity, and a total debt discount of $2,744,309. The convertible notes are recorded as a long-term liability, net of discount and issuance costs.</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">For the convertible notes for the quarter ended March 31, 2024, the Company recognized total interest expense of $361,552, including coupon interest expense of $102,750 amortization of debt discount and issuance costs of $258,802. As of December 31, 2023, the Notes principal balance as $6,850,000, unamortized discount was $2,636,346 and accrued interest was $44,525. As of March 31, 2024, the Notes principal balance as $6,850,000, unamortized discount was $2,377,544 and accrued interest was $147,275. The fair value of the convertible notes on March 31, 2024, calculated using a discounted cash flow analysis, was $6,185,934.</span></div> 6850000 1.18 5805083 1.18 5805083 1.475 6850000 525144 0.06 2025-11-21 1.18 P18M 2.36 P10D 1000000 1.15 P5Y 2 P10D 1000000 P1Y 2 P10D 1000000 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Series A</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Warrants</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Series B</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Warrants</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Expected term (in years)</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Risk‑free interest rate</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">4.55</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5.24</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Dividend yield</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Expected volatility</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">104.89</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">113.84</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Exercise price</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1.18</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1.48</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Stock price</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.95</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.95</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="margin-left: 9pt; text-indent: -9pt;"> </div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Black-Scholes value</div> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.55</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">0.28</div> </td> <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> P5Y P1Y 0.0455 0.0524 0 0 1.0489 1.1384 1.18 1.48 0.95 0.95 0.55 0.28 6850000 525144 2219165 2744309 361552 102750 258802 6850000 2636346 44525 6850000 2377544 147275 6185934 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold; font-family: 'Times New Roman';">(11)</div> </td> <td style="vertical-align: top;"> <div style="text-align: left; font-weight: bold; font-family: 'Times New Roman';">Stockholders’ Equity</div> </td> </tr> </table> </div> <div><span style="font-family: 'Times New Roman';"><br/> </span></div> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">On July 1, 2022, we filed a prospectus including an offering to sell up to $150 million in common and preferred stock, debt securities and warrants. Additionally, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler” or the “Sales Agent”) and filed a related prospectus establishing an “at-the-market” facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds up to $16.7 million at current market prices until all shares are sold. As of March 31, 2024, 3.9 million shares of common stock have been sold for aggregate proceeds of $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of March 31, 2024, the amount we are authorized to sell is subject to baby-shelf limitations.<br class="Apple-interchange-newline"/> </span></div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering (“pre-funded warrants”) and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock (“common warrants”). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services (“placement agent warrants”), collectively the (“April 2023 Financing”). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764. The Company intends to use the net proceeds from the offering for general corporate purposes.<br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of March 31, 2024, the Company had 22,099,347 shares of common stock outstanding, and no dividends have been declared or paid.</div> 150000000 16700000 3900000 8700000 1318000 1878722 3196722 191803 1.22 1.2199 3899813 547764 22099347 0 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(12)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Equity Incentive Plans and Warrants</span></div> </td> </tr> </table> </div> <div><br/> </div> <div><span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock-Based Awards</span><br/> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(a)</td> <td style="width: auto; vertical-align: top;"> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock Option Plans</div> </td> </tr> </table> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">Activity under the Company’s stock option plans for the three months ended March 31, 2024 was as follows:</div> <div> <br/> </div> <div style="margin-left: 36pt;"> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Number of</div> <div> options</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Weighted</div> <div>average</div> <div>exercise</div> <div> price</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Outstanding at December 31, 2023</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,102,030</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.00</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">708,821</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.97</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(62,618</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.59</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Outstanding at March 31, 2024</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,748,233</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">1.72</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Vested and exercisable at <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,208,627</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.63</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> <div><br/> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">Options granted under our 2021 Stock Option Plan for the three months ended March 31, 2024 to employees and nonemployees were 706,321 and 2,500, respectively and the weighted average exercise prices were $0.97 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.83 and $0.39, respectively and were estimated using the following Black-Scholes assumptions:</div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <br/> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-left: 36pt; text-align: left;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">Employee <br/> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> Nonemployee</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">6.25</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1.50</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="margin: 0px 0px 0px 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: -7.2pt; text-transform: none;">Risk‑free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">3.87</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4.53</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">% <br/> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">109.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">105.34</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table> </div> <div> <br/></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">No options were exercised for the three months ended March 31, 2024 under our stock option plans.<br/> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of March 31, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 849,647.<br/> </span></div> <div> <br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(b)</td> <td style="width: auto; vertical-align: top;"> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inducement Grants</div> </td> </tr> </table> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions:</span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">Inducement<br/> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">6.25<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="margin: 0px 0px 0px 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: -7.2pt; text-transform: none;">Risk‑free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">4.10</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">109.64</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> </table> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <br/> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">As of March 31, 2024, inducement grant awards of 250,000 shares were outstanding with a weighted average exercise price of $1.89, and 62,500 shares were vested and exercisable with a weighted average exercise price of $2.64.<br/> </div> <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;"><br/> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(c)</td> <td style="width: auto; vertical-align: top;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Share-Based Compensation Expense</span></td> </tr> </table> <div><br/> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; margin-left: 36pt;">The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss:</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </div> <div style="margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Three Months Ended <span style="font-size: 10pt;">March 31</span>,</span></td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;"> 2024</span> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">2023</span> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">30,327</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,059</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Sales and marketing</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,199</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,544</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">General and administrative</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41,059</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">34,439</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total share-based compensation expense</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">77,585</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> <div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; margin-left: 36pt;">As March 31<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, 2024</span>, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,411,405, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,256,183 of unrecognized expense is expected to be recognized over a weighted average period of 3.3 years.</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(d)</td> <td style="width: auto; vertical-align: top;"> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Employee Stock Purchase Plan (ESPP)<br/> </div> </td> </tr> </table> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div> </div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">March 31<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, 2024</span></span>, no shares of common stock were issued under the Company’s ESPP Plan. As of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">March 31<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, 2024</span></span>, the total number of shares of common stock reserved for future awards under the ESPP Plan was 603,518.</span> </div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(e)</td> <td style="width: auto; vertical-align: top;"> <div style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">April 2023 Financing</div> </td> </tr> </table> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 11, <span style="font-style: italic;">Stockholders’ Equity</span>), (ii) pre-funded warrants to purchase 1,878,722 shares of common stock, (iii) common warrants to purchase 3,196,722 shares of common stock. Additionally, common warrants to purchase 191,803 shares of common stock were issued to the placement agent compensation for services performed.</span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs.</span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.<br/> </span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;">The common stock was valued at $1,133,480, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions:</span></div> <div><br/> </div> <div style="margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Pre-funded</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Common</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>Expected term (in years)</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Risk‑free interest rate</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>Dividend yield</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Expected volatility</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>Exercise price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>0.0001</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1.095</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Stock price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Black-Scholes value <br/> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.86</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.58</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> <div> <br/> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholders’ equity.</div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-left: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2023, all pre-funded warrants were exercised for shares of common stock. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976</span>. As of March 31<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, 2024,</span> 68,809 placement agent warrants remain outstanding. </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">Activity under the Company’s stock option plans for the three months ended March 31, 2024 was as follows:</div> <div> <br/> </div> <div style="margin-left: 36pt;"> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Number of</div> <div> options</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Weighted</div> <div>average</div> <div>exercise</div> <div> price</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Outstanding at December 31, 2023</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,102,030</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.00</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">708,821</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.97</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(62,618</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.59</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Outstanding at March 31, 2024</span></td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,748,233</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">1.72</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Vested and exercisable at <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,208,627</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.63</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> 2102030 2 708821 0.97 62618 2.59 2748233 1.72 1208627 2.63 <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;">Options granted under our 2021 Stock Option Plan for the three months ended March 31, 2024 to employees and nonemployees were 706,321 and 2,500, respectively and the weighted average exercise prices were $0.97 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.83 and $0.39, respectively and were estimated using the following Black-Scholes assumptions:</div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <br/> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-left: 36pt; text-align: left;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">Employee <br/> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> Nonemployee</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">6.25</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1.50</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="margin: 0px 0px 0px 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: -7.2pt; text-transform: none;">Risk‑free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">3.87</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4.53</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">% <br/> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">109.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">%</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">105.34</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table> </div> 706321 2500 0.97 0.79 0.83 0.39 P6Y3M P1Y6M 0.0387 0.0453 0 0 1.0965 1.0534 0 849647 <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions:</span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">Inducement<br/> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">6.25<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="margin: 0px 0px 0px 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: -7.2pt; text-transform: none;">Risk‑free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">4.10</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">109.64</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">%</div> </td> </tr> </table> </div> 100000 1.1 P4Y 0.94 P6Y3M 0.041 0 1.0964 250000 1.89 62500 2.64 <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; margin-left: 36pt;">The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss:</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/> </div> <div style="margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Three Months Ended <span style="font-size: 10pt;">March 31</span>,</span></td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;"> 2024</span> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">2023</span> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">30,327</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,059</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Sales and marketing</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,199</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,544</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">General and administrative</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41,059</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">34,439</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total share-based compensation expense</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">77,585</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> 30327 25059 6199 -2544 41059 34439 77585 56954 1411405 155222 1256183 P3Y3M18D 0 603518 1318000 1878722 3196722 191803 0.0001 P5Y6M 1.095 P5Y 1.525 3899813 547764 <div style="margin-left: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-style: normal;">The common stock was valued at $1,133,480, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions:</span></div> <div><br/> </div> <div style="margin-left: 36pt;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Pre-funded</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Common</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>Expected term (in years)</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Risk‑free interest rate</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>Dividend yield</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Expected volatility</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>Exercise price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>0.0001</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1.095</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Stock price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Black-Scholes value <br/> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.86</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.58</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> 1133480 1615701 1854099 P4Y P4Y 0.0383 0.0383 0 0 1.0025 1.0025 0.0001 1.095 0.86 0.86 0.86 0.58 3352049 122994 122994 3687976 3687976 68809 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(13)</div> </td> <td style="text-align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Related‑Party Transactions</div> </td> </tr> </table> </div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 9). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Company’s board of directors.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2023 and quarters ended March 31, 2024 and 2023, a family member of the CEO was employed by the Company.</div> 5000000 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(14)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Net Loss per Share Attributable to Common Stockholders</div> </td> </tr> </table> </div> <div><br/> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table sets forth the computation of the basic and diluted net loss per share:</div> <div> <br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);"> <div style="color: rgb(0, 0, 0); text-indent: -18pt; margin-left: 18pt;">Net loss attributable to common stockholders, basic & diluted</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(3,599,510</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(2,946,257</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="margin-left: 9pt; text-indent: -9pt;"> </div> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">21,775,357<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">11,872,255</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Net loss per share attributable to common stockholders, basic and diluted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(0.17</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(0.25</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> </tr> </table> <div><br/> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive</span>:</span></div> <div> <br/> </div> <div style="text-align: left;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-weight: bold; text-align: center;">March 31, </div> <div style="font-weight: bold; text-align: center;">2024<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-weight: bold; text-align: center;">March 31,</div> <div style="font-weight: bold; text-align: center;">2023<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Options to purchase common stock</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>2,998,233</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,036,495</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with April 2023 financing</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with November 2023 financing<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Warrants to purchase common stock</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>201,578</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>233,460</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Total potential shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>14,878,786</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>1,269,955</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table sets forth the computation of the basic and diluted net loss per share:</div> <div> <br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);"> <div style="color: rgb(0, 0, 0); text-indent: -18pt; margin-left: 18pt;">Net loss attributable to common stockholders, basic & diluted</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(3,599,510</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(2,946,257</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="margin-left: 9pt; text-indent: -9pt;"> </div> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">21,775,357<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">11,872,255</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Net loss per share attributable to common stockholders, basic and diluted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(0.17</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(0.25</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">)</div> </td> </tr> </table> -3599510 -3599510 -2946257 -2946257 21775357 21775357 11872255 11872255 -0.17 -0.17 -0.25 -0.25 <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive</span>:</span></div> <div> <br/> </div> <div style="text-align: left;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-weight: bold; text-align: center;">March 31, </div> <div style="font-weight: bold; text-align: center;">2024<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-weight: bold; text-align: center;">March 31,</div> <div style="font-weight: bold; text-align: center;">2023<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Options to purchase common stock</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>2,998,233</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,036,495</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with April 2023 financing</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with November 2023 financing<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Warrants to purchase common stock</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>201,578</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>233,460</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman';">Total potential shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>14,878,786</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div>1,269,955</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> </div> 2998233 1036495 68809 0 11610166 0 201578 233460 14878786 1269955 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(15)</div> </td> <td style="text-align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income Taxes<br/> </div> </td> </tr> </table> </div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The effective tax rate of 0% for the three months ended March 31, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position.</div> 0 0 <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(16)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Subsequent Events</span></div> </td> </tr> </table> </div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">In April 2024, the Company sold 121,371 shares under the at-the-market facility, resulting in gross cash proceeds of $219,752.</span></span> </div> 121371 219752 false false false false